<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB01039</drugbank-id>
  <drugbank-id>APRD00405</drugbank-id>
  <drugbank-id>DB09545</drugbank-id>
  <name>Fenofibrate</name>
  <description>Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil].[A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591]&#13;
&#13;
Fenofibrate was granted FDA approval on 31 December 1993.[L8585]</description>
  <cas-number>49562-28-9</cas-number>
  <unii>U202363UOS</unii>
  <average-mass>360.831</average-mass>
  <monoisotopic-mass>360.112836867</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A185831</ref-id>
        <pubmed-id>27594083</pubmed-id>
        <citation>Wei X, Li P, Liu M, Du Y, Wang M, Zhang J, Wang J, Liu H, Liu X: Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2017 Apr;31(4). doi: 10.1002/bmc.3832. Epub 2016 Oct 10.</citation>
      </article>
      <article>
        <ref-id>A185936</ref-id>
        <pubmed-id>3318449</pubmed-id>
        <citation>Chapman MJ: Pharmacology of fenofibrate. Am J Med. 1987 Nov 27;83(5B):21-5. doi: 10.1016/0002-9343(87)90867-9.</citation>
      </article>
      <article>
        <ref-id>A36366</ref-id>
        <pubmed-id>9515185</pubmed-id>
        <citation>Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62. doi: 10.2165/00003088-199834020-00003.</citation>
      </article>
      <article>
        <ref-id>A185954</ref-id>
        <pubmed-id>2226216</pubmed-id>
        <citation>Balfour JA, McTavish D, Heel RC: Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990 Aug;40(2):260-90. doi: 10.2165/00003495-199040020-00007.</citation>
      </article>
      <article>
        <ref-id>A17495</ref-id>
        <pubmed-id>12582161</pubmed-id>
        <citation>Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, Staels B: The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83. Epub 2003 Feb 11.</citation>
      </article>
      <article>
        <ref-id>A185972</ref-id>
        <pubmed-id>23386599</pubmed-id>
        <citation>Laizure SC, Herring V, Hu Z, Witbrodt K, Parker RB: The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy. 2013 Feb;33(2):210-22. doi: 10.1002/phar.1194.</citation>
      </article>
      <article>
        <ref-id>A185984</ref-id>
        <pubmed-id>27599626</pubmed-id>
        <citation>Malatkova P, Kanavi M, Nobilis M, Wsol V: In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. doi: 10.1016/j.cbi.2016.09.001. Epub 2016 Sep 4.</citation>
      </article>
      <article>
        <ref-id>A186002</ref-id>
        <pubmed-id>19251819</pubmed-id>
        <citation>Liu A, Patterson AD, Yang Z, Zhang X, Liu W, Qiu F, Sun H, Krausz KW, Idle JR, Gonzalez FJ, Dai R: Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics. Drug Metab Dispos. 2009 Jun;37(6):1157-63. doi: 10.1124/dmd.108.025817. Epub 2009 Feb 27.</citation>
      </article>
      <article>
        <ref-id>A186005</ref-id>
        <pubmed-id>11330046</pubmed-id>
        <citation>Qi C, Zhu Y, Reddy JK: Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys. 2000;32 Spring:187-204.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L8585</ref-id>
        <title>FDA Approved Drug Products: Lipidil Fenofibrate Oral Capsules (Discontinued)</title>
        <url>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=019304</url>
      </link>
      <link>
        <ref-id>L8588</ref-id>
        <title>FDA Approved Drug Products: Fenofibrate Oral Tablets</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf</url>
      </link>
      <link>
        <ref-id>L8591</ref-id>
        <title>FDA Approved Drug Products: Fenofibrate Oral Capsules</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf</url>
      </link>
      <link>
        <ref-id>L8651</ref-id>
        <title>Cayman Chemicals: Fenofibrate MSDS</title>
        <url>https://www.caymanchem.com/msdss/10005368m.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>Jean-Francois Boyer, "Medicine based on fenofibrate, and a method of preparing it." U.S. Patent US4800079, issued January, 1988.</synthesis-reference>
  <indication>Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia.[L8588,L8591] Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.[L8588,L8591]</indication>
  <pharmacodynamics>Fenofibrate is a fibrate that activates peroxisome proliferator activated receptor alpha (PPARα) to alter lipid metabolism and treat primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia.[A186002,L8588,L8591] Fenofibrate requires once daily dosing and has a half life of 19-27 hours so its duration of action is long.[A36366,L8588,L8591] Fenofibrate capsules are given at a dose of 50-150mg daily so the therapeutic index is wide.[L8591] Patients should be counselled about the risk of rhabdomyolysis, myopathy, and cholelithiasis when taking fibrates.[L8588,L8591]</pharmacodynamics>
  <mechanism-of-action>Fenofibrate activates peroxisome proliferator activated receptor alpha (PPARα), increasing lipolysis, activating lipoprotein lipase, and reducing apoprotein C-III.[A186002,L8588,L8591] PPARα is a nuclear receptor and its activation alters lipid, glucose, and amino acid homeostasis.[A186002] Activation of PPARα activates transcription of gene transcription and translation that generates peroxisomes filled with hydrogen peroxide, reactive oxygen species, and hydroxyl radicals that also participate in lipolysis.[A186005] This mechanism of increased lipid metabolism is also associated with increased oxidative stress on the liver.[A186005] In rare cases this stress can lead to cirrhosis and chronic active hepatitis.[A186002,L8588,L8591]</mechanism-of-action>
  <toxicity>The oral LD&lt;sub&gt;50&lt;/sub&gt; in rats is &gt;2g/kg and in mice is 1600mg/kg.[L8651] The oral TDLO in rats is 9mg/kg.[L8651]&#13;
&#13;
Treat patients with supportive care including monitoring of vital signs and observing clinical status.[L8588,L8591] Recent overdose may be treated with inducing vomiting or gastric lavage.[L8588,L8591] Due to fenofibrate's extensive protein binding, hemodialysis is not expected to be useful.[A185936,L8588,L8591]</toxicity>
  <metabolism>Fenofibrate is completely hydrolyzed by liver carboxylesterase 1 to fenofibric acid.[A185972,L8588,L8591] Fenofibric acid is either glucuronidated or has its carbonyl group reduced to a benzhydrol that is then glucuronidated.[L8588,L8591] Glucuronidation of fenofibrate metabolites is mediated by UGT1A9.[A17495] Reduction of the carbonyl group is primarily mediated by CBR1 and minorly by AKR1C1, AKR1C2, AKR1C3, and AKR1B1.[A185984]</metabolism>
  <absorption>A single 300mg oral dose of fenofibrate reaches a C&lt;sub&gt;max&lt;/sub&gt; of 6-9.5mg/L with a T&lt;sub&gt;max&lt;/sub&gt; of 4-6h in healthy, fasting volunteers.[A185954]</absorption>
  <half-life>Fenofibric acid, the active metabolite of fenofibrate, has a half life of 23 hours.[L8588,L8591] Fenofibrate has a half life of 19-27 hours in healthy subjects and up to 143 hours in patients with renal failure.[A36366]</half-life>
  <protein-binding>Fenofibrate is 99% protein bound in serum,[L8588,L8591] primarily to albumin.[A185936]</protein-binding>
  <route-of-elimination>5-25% of a dose of fenofibrate is eliminated in the feces, while 60-88% is eliminated in the urine.[A185936,L8588,L8591] 70-75% of the dose recovered in the urine is in the form of fenofibryl glucuronide and 16% as fenofibric acid.[A185936]</route-of-elimination>
  <volume-of-distribution>The volume of distribution of fenofibrate is 0.89L/kg,[A185954] and can be as high as 60L.[A36366]</volume-of-distribution>
  <clearance> The oral clearance of fenofibrate is 1.1L/h in young adults and 1.2L/h in the elderly.[L8588,L8591]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.</description>
    <direct-parent>Benzophenones</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Benzophenones</subclass>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Aryl chlorides</alternative-parent>
    <alternative-parent>Aryl-phenylketones</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Chlorobenzenes</alternative-parent>
    <alternative-parent>Diphenylmethanes</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Phenol ethers</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Phenoxyacetic acid derivatives</alternative-parent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Aryl chloride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Aryl ketone</substituent>
    <substituent>Aryl-phenylketone</substituent>
    <substituent>Benzophenone</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Chlorobenzene</substituent>
    <substituent>Diphenylmethane</substituent>
    <substituent>Ether</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Ketone</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Phenol ether</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Phenoxyacetate</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester</synonym>
    <synonym language="english" coder="inn/usan">Fenofibrate</synonym>
    <synonym language="spanish" coder="inn">Fenofibrato</synonym>
    <synonym language="latin" coder="inn">Fenofibratum</synonym>
    <synonym language="english" coder="">Finofibrate</synonym>
    <synonym language="english" coder="">FNF</synonym>
    <synonym language="english" coder="">Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate</synonym>
    <synonym language="english" coder="">Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate</synonym>
    <synonym language="english" coder="">Procetofen</synonym>
  </synonyms>
  <products>
    <product>
      <name>Aa-feno-micro</name>
      <labeller>Aa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239864</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aa-feno-micro</name>
      <labeller>Aa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243180</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antara</name>
      <labeller>Oscient Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>67707-043</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>43 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Antara</name>
      <labeller>Oscient Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>67707-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>130 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Antara</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5498</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-12-27</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>130 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021695</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Antara</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>27437-107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021695</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Antara</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>27437-108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021695</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Antara</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>27437-109</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>43 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021695</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Antara</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>27437-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>130 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021695</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Apo-feno-super</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246859</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-feno-super</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246860</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-feno-super</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246861</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-fenofibrate Micro</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02364409</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-22</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cholib</name>
      <labeller>Mylan Products Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002559</ema-product-code>
      <ema-ma-number>EU/1/13/866/001</ema-ma-number>
      <started-marketing-on>2013-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Cholib</name>
      <labeller>Mylan Products Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002559</ema-product-code>
      <ema-ma-number>EU/1/13/866/002</ema-ma-number>
      <started-marketing-on>2013-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Cholib</name>
      <labeller>Mylan Products Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002559</ema-product-code>
      <ema-ma-number>EU/1/13/866/003</ema-ma-number>
      <started-marketing-on>2013-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Cholib</name>
      <labeller>Mylan Products Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002559</ema-product-code>
      <ema-ma-number>EU/1/13/866/004</ema-ma-number>
      <started-marketing-on>2013-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Cholib</name>
      <labeller>Mylan Products Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002559</ema-product-code>
      <ema-ma-number>EU/1/13/866/005</ema-ma-number>
      <started-marketing-on>2013-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Cholib</name>
      <labeller>Mylan Products Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002559</ema-product-code>
      <ema-ma-number>EU/1/13/866/006</ema-ma-number>
      <started-marketing-on>2013-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Dom-fenofibrate Micro</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240337</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-12-16</started-marketing-on>
      <ended-marketing-on>2018-10-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-fenofibrate Supra</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02251698</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-fenofibrate Supra</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02251701</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Feno-micro-200</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240360</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Karalex Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42043-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076520</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Karalex Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42043-171</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076520</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5994</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5575</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5697</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5660</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-518</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on>2012-07-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-519</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on>2012-07-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Med Health Pharma LLC.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-456</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-01</started-marketing-on>
      <ended-marketing-on>2012-06-21</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Med Health Pharma LLC.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-457</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-01</started-marketing-on>
      <ended-marketing-on>2012-06-21</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Med Health Pharma LLC.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-458</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-01</started-marketing-on>
      <ended-marketing-on>2012-06-21</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7548</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-0172</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-1074</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-0171</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-25</started-marketing-on>
      <ended-marketing-on>2015-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-528</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-25</started-marketing-on>
      <ended-marketing-on>2015-10-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-966</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>H2 Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>61269-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021612</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>H2 Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>61269-212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021612</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51655-009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/301</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51655-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/301</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51655-901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-831</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51655-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-595</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204598</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-596</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204598</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-6299</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2018-04-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-490</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-18</started-marketing-on>
      <ended-marketing-on>2016-02-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-495</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-18</started-marketing-on>
      <ended-marketing-on>2016-02-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>120 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-4718</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-319</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>70786-0522</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>70786-0511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-360</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-361</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-925</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-905</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7151</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-518</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207805</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-519</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207805</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-520</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207805</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4182</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-4717</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-898</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076520</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-493</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-27</started-marketing-on>
      <ended-marketing-on>2018-05-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-157</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-23</started-marketing-on>
      <ended-marketing-on>2017-03-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-2135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1450</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-14</started-marketing-on>
      <ended-marketing-on>2016-11-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>70786-5522</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-0173</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-5522</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on>2017-06-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6459</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-2021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-2115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-2042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-29</started-marketing-on>
      <ended-marketing-on>2018-06-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207378</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4265</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4358</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4264</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-292</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>130 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201748</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-248</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-13</started-marketing-on>
      <ended-marketing-on>2014-08-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>St. Marys Medical Park Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>60760-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-21</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>St. Marys Medical Park Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>60760-900</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-02</started-marketing-on>
      <ended-marketing-on>2018-03-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4297</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71610-027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-603</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-13</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076520</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4320</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>St. Marys Medical Park Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>60760-901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on>2016-10-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-1514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-311</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-309</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2459</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2016-10-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2857</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7213</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-653</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1275</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0741</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-290</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3255</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3044</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204598</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3056</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204598</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>KAISER FOUNDATION HOSPITALS</labeller>
      <ndc-id/>
      <ndc-product-code>0179-0097</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-03</started-marketing-on>
      <ended-marketing-on>2011-08-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0578</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0903</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3373</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Casper Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70199-027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021350</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Zydus Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68382-228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2018-11-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Zydus Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68382-230</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2019-01-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Zydus Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68382-269</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Zydus Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68382-270</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>KAISER FOUNDATION HOSPITALS</labeller>
      <ndc-id/>
      <ndc-product-code>0179-0091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-26</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>KAISER FOUNDATION HOSPITALS</labeller>
      <ndc-id/>
      <ndc-product-code>0179-0103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-03</started-marketing-on>
      <ended-marketing-on>2020-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4557</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208709</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3904</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4659</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA200884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4486</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3887</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA200884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208709</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-349</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>43 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090859</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-395</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>130 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090859</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>NCS HealthCare of KY, Inc dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8270</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210138</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1274</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2546</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-360</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-361</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Solco Healthcare US, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211080</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Solco Healthcare US, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211080</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Basiem</labeller>
      <ndc-id/>
      <ndc-product-code>69597-346</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-8628</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202676</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-8629</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202676</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-8630</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202676</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-22</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>43 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202579</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-22</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>130 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202579</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-900</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210138</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210138</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210705</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-119</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210705</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210705</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-448</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA200884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-449</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA200884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-362</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-363</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Ingenus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50742-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207564</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Ingenus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50742-202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207564</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Ingenus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50742-203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207564</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>43 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>130 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-223</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-224</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA200884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-440</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210782</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-439</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210782</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-438</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210782</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amerigen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43975-444</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209504</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amerigen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43975-305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209504</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amerigen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43975-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209504</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076520</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076520</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3842</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>35356-916</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Cipla USA Inc.,</labeller>
      <ndc-id/>
      <ndc-product-code>69097-894</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207378</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Cipla USA Inc.,</labeller>
      <ndc-id/>
      <ndc-product-code>69097-895</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207378</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Cipla USA Inc.,</labeller>
      <ndc-id/>
      <ndc-product-code>69097-896</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207378</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1262</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209950</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1263</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209950</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1260</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209951</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1261</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209951</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-739</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207378</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-740</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207378</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-741</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207378</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205566</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-581</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205566</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-582</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205566</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-4390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-4391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>120 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Cipla USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69097-459</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208709</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Cipla USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69097-458</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208709</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3066</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Perrigo New York Inc</labeller>
      <ndc-id/>
      <ndc-product-code>45802-315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Perrigo New York Inc</labeller>
      <ndc-id/>
      <ndc-product-code>45802-132</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-454</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-660</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0891</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208709</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-1211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208709</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0700</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-5511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-5522</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-298</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-443</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>43 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201748</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-444</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>130 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201748</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-827</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-328</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076509</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>St Mary's Medical Park Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>60760-660</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-0511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-0522</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-0533</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-835</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075868</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4983</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4992</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210138</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4988</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208709</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4991</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210138</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-1286</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210138</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Direct_Rx</labeller>
      <ndc-id/>
      <ndc-product-code>72189-026</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-360</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210476</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-361</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210476</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-360</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210476</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-361</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210476</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209660</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209660</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1522</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1523</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>120 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0872</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA200884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-1292</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA200884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7254</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2349</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210138</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>St. Mary's Medical Park Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>60760-411</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210138</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210138</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>43 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202252</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>130 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202252</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-635</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-636</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090715</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-5101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208709</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-940</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Institutional Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51079-599</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Mylan Institutional Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51079-608</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202856</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1988</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209660</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209660</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>NCS HealthCare of KY, Inc dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8165</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-11</started-marketing-on>
      <ended-marketing-on>2020-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-760</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-640</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076635</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-681</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>ANI Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62559-460</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>ANI Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62559-461</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-538</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209660</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209660</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-366</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-768</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-769</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-737</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-738</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4698</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207378</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>AustarPharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>35561-343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>AustarPharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>35561-344</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-067</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Teva Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7756</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on>2020-02-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Teva Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0093-2061</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2018-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Teva Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0093-2060</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2018-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Teva Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7755</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on>2020-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51407-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51407-091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51407-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51407-093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51407-094</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate</name>
      <labeller>Aa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02225980</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fenofibrate film coated</name>
      <labeller>Graviti Pharmaceuticals Private Limited</labeller>
      <ndc-id/>
      <ndc-product-code>69844-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210606</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate film coated</name>
      <labeller>Graviti Pharmaceuticals Private Limited</labeller>
      <ndc-id/>
      <ndc-product-code>69844-009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210606</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenofibrate Micro</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02286092</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-25</started-marketing-on>
      <ended-marketing-on>2017-07-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fenofibrate-S</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02356570</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-23</started-marketing-on>
      <ended-marketing-on>2017-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fenofibrate-S</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02356589</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-23</started-marketing-on>
      <ended-marketing-on>2017-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fenoglide</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>120 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022118</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenoglide</name>
      <labeller>Shore Therapeutics, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>52725-490</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022118</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenoglide</name>
      <labeller>Shore Therapeutics, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>52725-495</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>120 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022118</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenoglide</name>
      <labeller>Shionogi</labeller>
      <ndc-id/>
      <ndc-product-code>59630-490</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-07</started-marketing-on>
      <ended-marketing-on>2013-09-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenoglide</name>
      <labeller>Shionogi</labeller>
      <ndc-id/>
      <ndc-product-code>59630-495</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-07</started-marketing-on>
      <ended-marketing-on>2013-09-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>120 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenoglide</name>
      <labeller>Santarus, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68012-490</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022118</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenoglide</name>
      <labeller>Santarus, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68012-495</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>120 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022118</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fenomax</name>
      <labeller>Cipher Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02249995</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fenomax</name>
      <labeller>Cipher Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02250004</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lipidil Cap 100mg</name>
      <labeller>Laboratoires Fournier S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00885827</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-11</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lipidil Ez</name>
      <labeller>Bgp Pharma Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02269074</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lipidil Ez</name>
      <labeller>Bgp Pharma Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02269082</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lipidil Micro</name>
      <labeller>Bgp Pharma Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02146959</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2016-11-09</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lipidil Micro - Cap 67mg</name>
      <labeller>Laboratoires Fournier S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230283</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-05-27</started-marketing-on>
      <ended-marketing-on>2003-07-21</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lipidil Supra</name>
      <labeller>Bgp Pharma Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02241602</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lipidil Supra 100 mg</name>
      <labeller>Laboratoires Fournier S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02241601</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-03-16</started-marketing-on>
      <ended-marketing-on>2014-01-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lipofen</name>
      <labeller>CIPHER</labeller>
      <ndc-id/>
      <ndc-product-code>66277-246</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-10</started-marketing-on>
      <ended-marketing-on>2007-04-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lipofen</name>
      <labeller>CIPHER</labeller>
      <ndc-id/>
      <ndc-product-code>66277-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-10</started-marketing-on>
      <ended-marketing-on>2007-04-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lipofen</name>
      <labeller>CIPHER</labeller>
      <ndc-id/>
      <ndc-product-code>66277-248</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-10</started-marketing-on>
      <ended-marketing-on>2007-04-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lipofen</name>
      <labeller>Kowa Pharmaceuticals America Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66869-137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021612</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lipofen</name>
      <labeller>Kowa Pharmaceuticals America Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66869-147</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021612</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lofibra</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-01-24</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lofibra</name>
      <labeller>Teva Select Brands</labeller>
      <ndc-id/>
      <ndc-product-code>57844-322</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-10-11</started-marketing-on>
      <ended-marketing-on>2018-05-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>67 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lofibra</name>
      <labeller>Teva Select Brands</labeller>
      <ndc-id/>
      <ndc-product-code>57844-323</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-03</started-marketing-on>
      <ended-marketing-on>2018-07-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>134 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lofibra</name>
      <labeller>Teva Select Brands</labeller>
      <ndc-id/>
      <ndc-product-code>57844-324</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-03</started-marketing-on>
      <ended-marketing-on>2017-10-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lofibra</name>
      <labeller>Teva Select Brands</labeller>
      <ndc-id/>
      <ndc-product-code>57844-691</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-11-23</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lofibra</name>
      <labeller>Teva Select Brands</labeller>
      <ndc-id/>
      <ndc-product-code>57844-692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-11-23</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076433</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mint-fenofibrate E</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02465167</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-fenofibrate Micro</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240210</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-05-26</started-marketing-on>
      <ended-marketing-on>2017-08-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-fenofibrate</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231495</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-01-23</started-marketing-on>
      <ended-marketing-on>2005-08-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-fenofibrate Micronized</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243551</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-04-20</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-fenofibrate Micronized</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243552</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-04-20</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-fenofibrate-S</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02352370</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-fenofibrate-S</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02352389</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-feno-micro</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02249715</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-feno-micro</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02335875</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-fenofibrate</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02223600</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-29</started-marketing-on>
      <ended-marketing-on>2012-09-04</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-fenofibrate Micro</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247489</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-23</started-marketing-on>
      <ended-marketing-on>2016-10-25</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-fenofibrate Supra</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02251663</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-fenofibrate Supra</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02251671</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-fenofibrate</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231496</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-fenofibrate Micro</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231780</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-04-19</started-marketing-on>
      <ended-marketing-on>2016-10-28</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-fenofibrate Micro</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02273551</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-11-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-fenofibrate Supra</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02251728</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-fenofibrate Supra</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02251736</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro-feno-super - 100</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02310228</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-10</started-marketing-on>
      <ended-marketing-on>2019-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro-feno-super - 160</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02310236</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-fenofibrate Micro</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371405</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-29</started-marketing-on>
      <ended-marketing-on>2015-08-21</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-fenofibrate S</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391309</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-fenofibrate S</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391317</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-fenofibrate Mc</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02250039</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-05</started-marketing-on>
      <ended-marketing-on>2019-09-16</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-fenofibrate Micro</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247306</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-03-12</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Fenofibrate E</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02390698</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Fenofibrate E</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02390701</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Fenofibrate S</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02288044</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Fenofibrate S</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02288052</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Fenofibrate S</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02288060</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sunpharma Fenofibrate E</name>
      <labeller>Sun Pharma Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02454696</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-fenofibrate-S</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02289083</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-20</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-fenofibrate-S</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02289091</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-20</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5224</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-02-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4597</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-02-04</started-marketing-on>
      <ended-marketing-on>2005-12-04</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021203</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-5750</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2009-09-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-272</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0956</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2017-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>49999-885</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-20</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6966</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2013-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6967</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2015-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2899</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>AbbVie Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0074-6122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2017-06-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>AbbVie Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0074-6123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-05</started-marketing-on>
      <ended-marketing-on>2019-01-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>AbbVie Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0074-3173</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>48 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricor</name>
      <labeller>AbbVie Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0074-3189</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>145 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triglide</name>
      <labeller>First Horizon Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>59630-480</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-03</started-marketing-on>
      <ended-marketing-on>2007-03-23</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triglide</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5784</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-21</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triglide</name>
      <labeller>Shionogi</labeller>
      <ndc-id/>
      <ndc-product-code>59630-485</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triglide</name>
      <labeller>Key Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70868-013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-11</started-marketing-on>
      <ended-marketing-on>2018-10-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triglide</name>
      <labeller>Casper Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70199-013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>160 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Fenogal</name>
      <company>SMB Laboratories</company>
    </international-brand>
    <international-brand>
      <name>Lipanthyl</name>
      <company>Abbott</company>
    </international-brand>
    <international-brand>
      <name>Lipantil</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Lipidil</name>
      <company>lbirn</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Cholib</name>
      <ingredients>Fenofibrate + Simvastatin</ingredients>
    </mixture>
    <mixture>
      <name>Cholib</name>
      <ingredients>Fenofibrate + Simvastatin</ingredients>
    </mixture>
    <mixture>
      <name>Cholib</name>
      <ingredients>Fenofibrate + Simvastatin</ingredients>
    </mixture>
    <mixture>
      <name>Cholib</name>
      <ingredients>Fenofibrate + Simvastatin</ingredients>
    </mixture>
    <mixture>
      <name>Cholib</name>
      <ingredients>Fenofibrate + Simvastatin</ingredients>
    </mixture>
    <mixture>
      <name>Cholib</name>
      <ingredients>Fenofibrate + Simvastatin</ingredients>
    </mixture>
    <mixture>
      <name>Triglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Antara</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Antara</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenoglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenoglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenoglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Triglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lofibra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Antara</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenoglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenoglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Triglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Triglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lofibra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lofibra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lofibra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lofibra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lofibra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipofen</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipofen</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipofen</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Antara</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Antara</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipofen</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipofen</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Triglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenoglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenoglide</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate film coated</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate film coated</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricor</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Antara</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Antara</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Aa-feno-micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Feno-micro-200</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Aa-feno-micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-feno-super</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-feno-super</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-fenofibrate Mc</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Fenofibrate S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Fenofibrate S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Teva-fenofibrate-S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Pro-feno-super - 100</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Pro-feno-super - 160</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Fenofibrate E</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Fenofibrate E</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipidil Cap 100mg</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Nu-fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipidil Micro - Cap 67mg</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Novo-fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipidil Supra 100 mg</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Ava-fenofibrate Micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Q-fenofibrate Micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-feno-super</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenomax</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Dom-fenofibrate Supra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Dom-fenofibrate Supra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-fenofibrate Supra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-fenofibrate Supra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Fenofibrate S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Ran-fenofibrate S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Ran-fenofibrate S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Novo-fenofibrate Micronized</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Novo-fenofibrate Micronized</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-fenofibrate-S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-fenofibrate-S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-fenofibrate</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Sunpharma Fenofibrate E</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Riva-fenofibrate Micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipidil Ez</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipidil Ez</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-fenofibrate Micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>PHL-fenofibrate Micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipidil Micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenomax</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-fenofibrate Micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate Micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate-S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Fenofibrate-S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Dom-fenofibrate Micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-fenofibrate Micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>PHL-fenofibrate Supra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>PHL-fenofibrate Supra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Teva-fenofibrate-S</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Lipidil Supra</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Mint-fenofibrate E</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Nu-feno-micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
    <mixture>
      <name>Nu-feno-micro</name>
      <ingredients>Fenofibrate</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Abbott Laboratories Ltd.</name>
      <url>http://www.abbott.com</url>
    </packager>
    <packager>
      <name>Amerisource Health Services Corp.</name>
      <url>http://www.amerisourcebergen.com</url>
    </packager>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Atlantic Biologicals Corporation</name>
      <url>http://www.atlanticbiologicals.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Catalent Pharma Solutions</name>
      <url>http://www.catalent.com</url>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Ethypharm</name>
      <url>http://www.ethypharm-pharmaceutical.com</url>
    </packager>
    <packager>
      <name>Fournier Pharma Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Galephar Pharmaceutical Research Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Gate Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Global Pharmaceuticals</name>
      <url>http://www.globalphar.com</url>
    </packager>
    <packager>
      <name>Impax Laboratories Inc.</name>
      <url>http://www.impaxlabs.com</url>
    </packager>
    <packager>
      <name>Karalex Pharmaceuticals</name>
      <url>http://www.karalexpharma.com</url>
    </packager>
    <packager>
      <name>Kowa Pharmaceuticals America Inc.</name>
      <url>http://www.kowapharma.com</url>
    </packager>
    <packager>
      <name>Laboratories Fournier Sca</name>
      <url/>
    </packager>
    <packager>
      <name>Lake Erie Medical and Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Lupin Pharmaceuticals Inc.</name>
      <url>http://www.lupinpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Mikart Inc.</name>
      <url>http://www.mikart.com</url>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Mutual Pharmaceutical Co.</name>
      <url/>
    </packager>
    <packager>
      <name>Mylan</name>
      <url>http://www.mylan.com</url>
    </packager>
    <packager>
      <name>Novopharm Ltd.</name>
      <url/>
    </packager>
    <packager>
      <name>Oscient Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Pharmacy Service Center</name>
      <url/>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Promex Medical Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Ranbaxy Laboratories</name>
      <url>http://www.ranbaxy.com</url>
    </packager>
    <packager>
      <name>Reliant Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Resource Optimization and Innovation LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Sciele Pharma Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Shionogi Pharma Inc.</name>
      <url>http://www.shionogi-inc.com</url>
    </packager>
    <packager>
      <name>Skyepharma Production Sas</name>
      <url>http://www.skyepharma.fr</url>
    </packager>
    <packager>
      <name>Southwood Pharmaceuticals</name>
      <url>http://www.southwoodhealthcare.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>United Research Laboratories Inc.</name>
      <url>http://www.urlpharma.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Fenofibrate Micronized 67 mg capsule</description>
      <cost currency="USD">1.0</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Apo-Feno-Micro 200 mg Capsule</description>
      <cost currency="USD">1.14</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Fenofibrate Micro 200 mg Capsule</description>
      <cost currency="USD">1.14</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Mylan-Fenofibrate Micro 200 mg Capsule</description>
      <cost currency="USD">1.14</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Novo-Fenofibrate Micronized 200 mg Capsule</description>
      <cost currency="USD">1.14</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Pms-Fenofibrate Micro 200 mg Capsule</description>
      <cost currency="USD">1.14</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Ratio-Fenofibrate Mc 200 mg Capsule</description>
      <cost currency="USD">1.14</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Lipidil Supra 100 mg Tablet</description>
      <cost currency="USD">1.22</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lipidil Micro 200 mg Capsule</description>
      <cost currency="USD">1.23</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Lofibra 67 mg capsule</description>
      <cost currency="USD">1.26</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Lipidil Supra  160 mg Tablet</description>
      <cost currency="USD">1.4</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Triglide 50 mg tablet</description>
      <cost currency="USD">1.49</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Tricor 48 mg tablet</description>
      <cost currency="USD">1.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fenoglide 40 mg tablet</description>
      <cost currency="USD">1.72</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fenofibrate Micronized 134 mg capsule</description>
      <cost currency="USD">1.79</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Antara 43 mg capsule</description>
      <cost currency="USD">1.8</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Lofibra 134 mg capsule</description>
      <cost currency="USD">2.03</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Fenofibrate 160 mg tablet</description>
      <cost currency="USD">2.38</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fenofibrate 160 mg</description>
      <cost currency="USD">2.47</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fenofibrate Micronized 200 mg capsule</description>
      <cost currency="USD">2.77</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Lofibra 160 mg tablet</description>
      <cost currency="USD">3.11</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lofibra 200 mg capsule</description>
      <cost currency="USD">3.25</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Lipofen 150 mg capsule</description>
      <cost currency="USD">3.55</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Tricor 145 mg tablet</description>
      <cost currency="USD">4.69</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Antara 130 mg capsule</description>
      <cost currency="USD">5.13</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Fenoglide 120 mg tablet</description>
      <cost currency="USD">5.17</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Triglide 160 mg tablet</description>
      <cost currency="USD">6.39</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Feno-Micro 67 mg Capsule</description>
      <cost currency="USD">0.45</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Novo-Fenofibrate Micronized 67 mg Capsule</description>
      <cost currency="USD">0.45</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Apo-Fenofibrate 100 mg Capsule</description>
      <cost currency="USD">0.64</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Apo-Feno-Super 100 mg Tablet</description>
      <cost currency="USD">0.68</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Fenofibrate-S 100 mg Tablet</description>
      <cost currency="USD">0.68</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Fenofibrate S 100 mg Tablet</description>
      <cost currency="USD">0.68</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Feno-Super  160 mg Tablet</description>
      <cost currency="USD">0.79</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Fenofibrate-S  160 mg Tablet</description>
      <cost currency="USD">0.79</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Fenofibrate S  160 mg Tablet</description>
      <cost currency="USD">0.79</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fenofibrate 54 mg tablet</description>
      <cost currency="USD">0.81</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lofibra 54 mg tablet</description>
      <cost currency="USD">0.99</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Acids, Acyclic</category>
      <mesh-id>D000144</mesh-id>
    </category>
    <category>
      <category>Agents Causing Muscle Toxicity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Benzophenones</category>
      <mesh-id>D001577</mesh-id>
    </category>
    <category>
      <category>BSEP/ABCB11 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Butyrates</category>
      <mesh-id>D002087</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2A6 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2A6 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 Inhibitors</category>
      <mesh-id>D065689</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Inhibitors</category>
      <mesh-id>D065687</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C9 Inhibitors</category>
      <mesh-id>D065688</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Drugs that are Mainly Renally Excreted</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ethers</category>
      <mesh-id>D004987</mesh-id>
    </category>
    <category>
      <category>Fatty Acids</category>
      <mesh-id>D005227</mesh-id>
    </category>
    <category>
      <category>Fatty Acids, Volatile</category>
      <mesh-id>D005232</mesh-id>
    </category>
    <category>
      <category>Fibric Acids</category>
      <mesh-id>D058607</mesh-id>
    </category>
    <category>
      <category>Fribic Acid Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hypolipidemic Agents</category>
      <mesh-id>D000960</mesh-id>
    </category>
    <category>
      <category>Isobutyrates</category>
      <mesh-id>D058610</mesh-id>
    </category>
    <category>
      <category>Ketones</category>
      <mesh-id>D007659</mesh-id>
    </category>
    <category>
      <category>Lipid Modifying Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Lipid Modifying Agents, Plain</category>
      <mesh-id/>
    </category>
    <category>
      <category>Lipid Regulating Agents</category>
      <mesh-id>D057847</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Noxae</category>
      <mesh-id>D009676</mesh-id>
    </category>
    <category>
      <category>P-glycoprotein inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peroxisome Proliferator Receptor alpha Agonist</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peroxisome Proliferator-activated Receptor alpha Agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Phenols</category>
      <mesh-id>D010636</mesh-id>
    </category>
    <category>
      <category>Phenyl Ethers</category>
      <mesh-id>D010647</mesh-id>
    </category>
    <category>
      <category>Toxic Actions</category>
      <mesh-id>D004786</mesh-id>
    </category>
    <category>
      <category>UGT1A9 Substrates</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>130 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>30 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>43 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>90 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>100 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>134 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>150 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>200 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>67 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>145 mg/301</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>160 mg/301</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>54 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>145 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>160 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>48 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>54 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>145 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>160 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>48 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>120 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>40 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>54 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>145 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>160 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>48 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="C10BA03">
      <level code="C10BA">HMG CoA reductase inhibitors in combination with other lipid modifying agents</level>
      <level code="C10B">LIPID MODIFYING AGENTS, COMBINATIONS</level>
      <level code="C10">LIPID MODIFYING AGENTS</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
    <atc-code code="C10AB05">
      <level code="C10AB">Fibrates</level>
      <level code="C10A">LIPID MODIFYING AGENTS, PLAIN</level>
      <level code="C10">LIPID MODIFYING AGENTS</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
    <atc-code code="C10BA04">
      <level code="C10BA">HMG CoA reductase inhibitors in combination with other lipid modifying agents</level>
      <level code="C10B">LIPID MODIFYING AGENTS, COMBINATIONS</level>
      <level code="C10">LIPID MODIFYING AGENTS</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>24:06.06</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01039.pdf?1265922795</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB01039.pdf?1265922735</msds>
  <patents>
    <patent>
      <number>5145684</number>
      <country>United States</country>
      <approved>1992-09-08</approved>
      <expires>2011-01-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2487054</number>
      <country>Canada</country>
      <approved>2008-03-18</approved>
      <expires>2023-05-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2219475</number>
      <country>Canada</country>
      <approved>2002-07-09</approved>
      <expires>2017-12-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8124125</number>
      <country>United States</country>
      <approved>2012-02-28</approved>
      <expires>2024-10-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8481078</number>
      <country>United States</country>
      <approved>2013-07-09</approved>
      <expires>2024-10-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7658944</number>
      <country>United States</country>
      <approved>2010-02-09</approved>
      <expires>2024-12-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9173847</number>
      <country>United States</country>
      <approved>2015-11-03</approved>
      <expires>2024-10-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6277405</number>
      <country>United States</country>
      <approved>2001-08-21</approved>
      <expires>2018-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7037529</number>
      <country>United States</country>
      <approved>2006-05-02</approved>
      <expires>2018-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6074670</number>
      <country>United States</country>
      <approved>2000-06-13</approved>
      <expires>2018-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7041319</number>
      <country>United States</country>
      <approved>2006-05-09</approved>
      <expires>2018-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6652881</number>
      <country>United States</country>
      <approved>2003-11-25</approved>
      <expires>2018-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6589552</number>
      <country>United States</country>
      <approved>2003-07-08</approved>
      <expires>2018-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6696084</number>
      <country>United States</country>
      <approved>2004-02-24</approved>
      <expires>2021-09-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6375986</number>
      <country>United States</country>
      <approved>2002-04-23</approved>
      <expires>2020-09-21</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7320802</number>
      <country>United States</country>
      <approved>2008-01-22</approved>
      <expires>2023-02-21</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7276249</number>
      <country>United States</country>
      <approved>2007-10-02</approved>
      <expires>2023-02-21</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8026281</number>
      <country>United States</country>
      <approved>2011-09-27</approved>
      <expires>2025-04-22</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9314447</number>
      <country>United States</country>
      <approved>2016-04-19</approved>
      <expires>2033-05-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7863331</number>
      <country>United States</country>
      <approved>2011-01-04</approved>
      <expires>2020-08-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7101574</number>
      <country>United States</country>
      <approved>2006-09-05</approved>
      <expires>2020-08-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Increased absorption- take with meals.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>Troglitazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Reserpine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>Progesterone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Chlorpromazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>Cimetidine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>Bosentan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>Vinblastine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>Tamoxifen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00845</drugbank-id>
      <name>Clofazimine</name>
      <description>Clofazimine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>Glyburide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>Fusidic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>Simeprevir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>Lenvatinib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>Letermovir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14057</drugbank-id>
      <name>Valinomycin</name>
      <description>Valinomycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Phenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Fosphenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00636</drugbank-id>
      <name>Clofibrate</name>
      <description>The risk or severity of adverse effects can be increased when Clofibrate is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The risk or severity of adverse effects can be increased when Fenofibrate is combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01393</drugbank-id>
      <name>Bezafibrate</name>
      <description>The risk or severity of adverse effects can be increased when Fenofibrate is combined with Bezafibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08983</drugbank-id>
      <name>Etofibrate</name>
      <description>The risk or severity of adverse effects can be increased when Fenofibrate is combined with Etofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09064</drugbank-id>
      <name>Ciprofibrate</name>
      <description>The risk or severity of adverse effects can be increased when Fenofibrate is combined with Ciprofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13433</drugbank-id>
      <name>Simfibrate</name>
      <description>The risk or severity of adverse effects can be increased when Fenofibrate is combined with Simfibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13460</drugbank-id>
      <name>Ronifibrate</name>
      <description>The risk or severity of adverse effects can be increased when Fenofibrate is combined with Ronifibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13780</drugbank-id>
      <name>Aluminium clofibrate</name>
      <description>The risk or severity of adverse effects can be increased when Fenofibrate is combined with Aluminium clofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13849</drugbank-id>
      <name>Clofibride</name>
      <description>The risk or severity of adverse effects can be increased when Fenofibrate is combined with Clofibride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>The risk or severity of adverse effects can be increased when Fenofibrate is combined with Fenofibric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>The serum concentration of Ezetimibe can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02123</drugbank-id>
      <name>Glycochenodeoxycholic Acid</name>
      <description>The therapeutic efficacy of Glycochenodeoxycholic Acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>The therapeutic efficacy of Cholic Acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02691</drugbank-id>
      <name>Glycocholic acid</name>
      <description>The therapeutic efficacy of Glycocholic acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic acid</name>
      <description>The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The therapeutic efficacy of Taurocholic acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05990</drugbank-id>
      <name>Obeticholic acid</name>
      <description>The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06777</drugbank-id>
      <name>Chenodeoxycholic acid</name>
      <description>The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08833</drugbank-id>
      <name>Taurochenodeoxycholic acid</name>
      <description>The therapeutic efficacy of Taurochenodeoxycholic acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08834</drugbank-id>
      <name>Tauroursodeoxycholic acid</name>
      <description>The therapeutic efficacy of Tauroursodeoxycholic acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08857</drugbank-id>
      <name>Bamet-UD2</name>
      <description>The therapeutic efficacy of Bamet-UD2 can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11789</drugbank-id>
      <name>Hyodeoxycholic Acid</name>
      <description>The therapeutic efficacy of Hyodeoxycholic Acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01586</drugbank-id>
      <name>Ursodeoxycholic acid</name>
      <description>The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Glimepiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Acetohexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Tolazamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Glipizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Gliclazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Gliquidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Glisoxepide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Glibornuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Carbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Metahexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00375</drugbank-id>
      <name>Colestipol</name>
      <description>Colestipol can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00658</drugbank-id>
      <name>Sevelamer</name>
      <description>Sevelamer can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00930</drugbank-id>
      <name>Colesevelam</name>
      <description>Colesevelam can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Fenofibrate is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Fenofibrate is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when Fenofibrate is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Fenofibrate is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Fenofibrate is combined with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Tacrolimus may increase the nephrotoxic activities of Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00607</drugbank-id>
      <name>Nafcillin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Nafcillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00745</drugbank-id>
      <name>Modafinil</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Modafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06442</drugbank-id>
      <name>Avasimibe</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Avasimibe.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14240</drugbank-id>
      <name>Echinacea</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Echinacea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Pentobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Mitotane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of Fenofibrate can be increased when combined with St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09280</drugbank-id>
      <name>Lumacaftor</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Lumacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Rifamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Miconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01406</drugbank-id>
      <name>Danazol</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Danazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Seproxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Benidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14019</drugbank-id>
      <name>Fosnetupitant</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Fosnetupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Voriconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Delavirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Loperamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Telithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Itraconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Naloxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Posaconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02520</drugbank-id>
      <name>Ditiocarb</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Ditiocarb.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Telaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Cobicistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09101</drugbank-id>
      <name>Elvitegravir</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Elvitegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11730</drugbank-id>
      <name>Ribociclib</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Ribociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11779</drugbank-id>
      <name>Danoprevir</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Danoprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13179</drugbank-id>
      <name>Troleandomycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Troleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The metabolism of Terfenadine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The metabolism of Ergotamine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The metabolism of Conivaptan can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The metabolism of Tipranavir can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The metabolism of Saquinavir can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The metabolism of Darunavir can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The metabolism of Lopinavir can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The metabolism of Boceprevir can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Pravastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Cerivastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Fluvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Rosuvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06693</drugbank-id>
      <name>Mevastatin</name>
      <description>The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Mevastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Pitavastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>Olmesartan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Atenolol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>Atropine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00693</drugbank-id>
      <name>Fluorescein</name>
      <description>Fluorescein may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>Telmisartan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05804</drugbank-id>
      <name>Prasterone sulfate</name>
      <description>Fenofibrate may decrease the excretion rate of Prasterone sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09374</drugbank-id>
      <name>Indocyanine green acid form</name>
      <description>Fenofibrate may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12319</drugbank-id>
      <name>Benzbromarone</name>
      <description>Fenofibrate may decrease the excretion rate of Benzbromarone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12712</drugbank-id>
      <name>Pilsicainide</name>
      <description>Fenofibrate may decrease the excretion rate of Pilsicainide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13751</drugbank-id>
      <name>Glycyrrhizic acid</name>
      <description>Fenofibrate may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>Fenofibrate may decrease the excretion rate of Repaglinide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>Disulfiram may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>Fenofibrate may decrease the excretion rate of Nitrendipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>Icosapent may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00229</drugbank-id>
      <name>Cefotiam</name>
      <description>Cefotiam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Mesalazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00267</drugbank-id>
      <name>Cefmenoxime</name>
      <description>Cefmenoxime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00274</drugbank-id>
      <name>Cefmetazole</name>
      <description>Cefmetazole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>Pamidronic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>Tenofovir disoproxil may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00369</drugbank-id>
      <name>Cidofovir</name>
      <description>Cidofovir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>Triamterene may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00430</drugbank-id>
      <name>Cefpiramide</name>
      <description>Cefpiramide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00438</drugbank-id>
      <name>Ceftazidime</name>
      <description>Ceftazidime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00447</drugbank-id>
      <name>Loracarbef</name>
      <description>Loracarbef may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>Framycetin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00456</drugbank-id>
      <name>Cefalotin</name>
      <description>Cefalotin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>Nabumetone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>Ketorolac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>Tenoxicam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00479</drugbank-id>
      <name>Amikacin</name>
      <description>Amikacin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>Celecoxib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00493</drugbank-id>
      <name>Cefotaxime</name>
      <description>Cefotaxime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>Tolmetin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>Foscarnet may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>Rofecoxib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>Piroxicam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>Cephalexin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>Fenoprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00577</drugbank-id>
      <name>Valaciclovir</name>
      <description>Valaciclovir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>Valdecoxib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>Diclofenac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>Sulindac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00626</drugbank-id>
      <name>Bacitracin</name>
      <description>Bacitracin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>Amphotericin B may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>Tobramycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00689</drugbank-id>
      <name>Cephaloglycin</name>
      <description>Cephaloglycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00718</drugbank-id>
      <name>Adefovir dipivoxil</name>
      <description>Adefovir dipivoxil may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Pentamidine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>Etodolac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>Mefenamic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>Acyclovir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Naproxen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Sulfasalazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>Gentamicin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>Phenylbutazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>Meloxicam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Carprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>Cefaclor may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Diflunisal may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>Etacrynic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00923</drugbank-id>
      <name>Ceforanide</name>
      <description>Ceforanide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>Meclofenamic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>Netilmicin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>Carboplatin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>Oxaprozin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>Neomycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>Ketoprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Balsalazide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01066</drugbank-id>
      <name>Cefditoren</name>
      <description>Cefditoren may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>Streptomycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01111</drugbank-id>
      <name>Colistimethate</name>
      <description>Colistimethate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01112</drugbank-id>
      <name>Cefuroxime</name>
      <description>Cefuroxime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01139</drugbank-id>
      <name>Cefapirin</name>
      <description>Cefapirin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01140</drugbank-id>
      <name>Cefadroxil</name>
      <description>Cefadroxil may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01150</drugbank-id>
      <name>Cefprozil</name>
      <description>Cefprozil may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>Kanamycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>Ceftriaxone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Olsalazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>Lumiracoxib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01326</drugbank-id>
      <name>Cefamandole</name>
      <description>Cefamandole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01327</drugbank-id>
      <name>Cefazolin</name>
      <description>Cefazolin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01328</drugbank-id>
      <name>Cefonicid</name>
      <description>Cefonicid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>Cefoperazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01330</drugbank-id>
      <name>Cefotetan</name>
      <description>Cefotetan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01331</drugbank-id>
      <name>Cefoxitin</name>
      <description>Cefoxitin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01332</drugbank-id>
      <name>Ceftizoxime</name>
      <description>Ceftizoxime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>Cefradine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>Magnesium salicylate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>Salsalate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>Choline magnesium trisalicylate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01413</drugbank-id>
      <name>Cefepime</name>
      <description>Cefepime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01414</drugbank-id>
      <name>Cefacetrile</name>
      <description>Cefacetrile may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>Ceftibuten may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01416</drugbank-id>
      <name>Cefpodoxime</name>
      <description>Cefpodoxime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>Antrafenine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>Paromomycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>Aminophenazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>Antipyrine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>Tiaprofenic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>Etoricoxib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02247</drugbank-id>
      <name>Hydrolyzed Cephalothin</name>
      <description>Hydrolyzed Cephalothin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03450</drugbank-id>
      <name>Cephalothin Group</name>
      <description>Cephalothin Group may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>Oxyphenbutazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>Ribostamycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>Geneticin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>Niflumic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04570</drugbank-id>
      <name>Latamoxef</name>
      <description>Latamoxef may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>Apramycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>Gentamicin C1a may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>Neamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>Benoxaprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>Metamizole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>Zomepirac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04918</drugbank-id>
      <name>Ceftobiprole</name>
      <description>Ceftobiprole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>Cimicoxib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06590</drugbank-id>
      <name>Ceftaroline fosamil</name>
      <description>Ceftaroline fosamil may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>Arbekacin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>Lornoxicam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>Aceclofenac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>Zaltoprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>Azapropazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>Felbinac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>Puromycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>Parecoxib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>Salicylamide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>Kebuzone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>Isoxicam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>Indoprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>Ibuproxam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>Floctafenine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>Fenbufen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>Etofenamate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>Epirizole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09008</drugbank-id>
      <name>Cefaloridine</name>
      <description>Cefaloridine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09062</drugbank-id>
      <name>Cefminox</name>
      <description>Cefminox may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>Benzydamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>Loxoprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>Dexibuprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>Dexketoprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>Droxicam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>Tolfenamic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>Firocoxib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>Clonixin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>Morniflumate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Propacetamol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>Talniflumate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>Tenofovir alafenamide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11367</drugbank-id>
      <name>Cefroxadine</name>
      <description>Cefroxadine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>Robenacoxib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>Tepoxalin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>Dihydrostreptomycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>Flunixin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>Hygromycin B may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11935</drugbank-id>
      <name>Flomoxef</name>
      <description>Flomoxef may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12151</drugbank-id>
      <name>Brincidofovir</name>
      <description>Brincidofovir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>Indobufen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>Sisomicin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>Tinoridine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>Alclofenac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>Fentiazac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>Suxibuzone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13266</drugbank-id>
      <name>Cefatrizine</name>
      <description>Cefatrizine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>Dibekacin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>Micronomicin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>Bumadizone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>Alminoprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>Flunoxaprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>Feprazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>Difenpiramide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>Nifenazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>Lonazolac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13461</drugbank-id>
      <name>Cefcapene</name>
      <description>Cefcapene may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13470</drugbank-id>
      <name>Cefodizime</name>
      <description>Cefodizime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>Tenidap may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13499</drugbank-id>
      <name>Cefsulodin</name>
      <description>Cefsulodin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>Bendazac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13504</drugbank-id>
      <name>Cefetamet</name>
      <description>Cefetamet may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>Pranoprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>Propyphenazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>Proglumetacin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>Guacetisal may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>Isepamicin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>Ethenzamide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>Carbaspirin calcium may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>Mofebutazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13638</drugbank-id>
      <name>Cefbuperazone</name>
      <description>Cefbuperazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>Proquazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>Benorilate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13667</drugbank-id>
      <name>Cefozopran</name>
      <description>Cefozopran may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>Bekanamycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13682</drugbank-id>
      <name>Cefpirome</name>
      <description>Cefpirome may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>Pirprofen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13778</drugbank-id>
      <name>Cefazedone</name>
      <description>Cefazedone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>Acemetacin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13821</drugbank-id>
      <name>Ceftezole</name>
      <description>Ceftezole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>Imidazole salicylate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13868</drugbank-id>
      <name>Adefovir</name>
      <description>Adefovir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>SC-236 may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>NS-398 may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>Tenofovir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14713</drugbank-id>
      <name>Inotersen</name>
      <description>Inotersen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01438</drugbank-id>
      <name>Phenazopyridine</name>
      <description>Phenazopyridine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>Givosiran may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>Goserelin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>Salmon Calcitonin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>Desmopressin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>Aldesleukin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>Tositumomab may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00115</drugbank-id>
      <name>Cyanocobalamin</name>
      <description>Cyanocobalamin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>Folic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00165</drugbank-id>
      <name>Pyridoxine</name>
      <description>Pyridoxine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>Fluvoxamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Amphetamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>Cevimeline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>Lorazepam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00190</drugbank-id>
      <name>Carbidopa</name>
      <description>Carbidopa may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>Fluconazole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00198</drugbank-id>
      <name>Oseltamivir</name>
      <description>Oseltamivir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00200</drugbank-id>
      <name>Hydroxocobalamin</name>
      <description>Hydroxocobalamin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00225</drugbank-id>
      <name>Gadodiamide</name>
      <description>Gadodiamide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>Pregabalin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>Butabarbital may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>Benzatropine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>Doxycycline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>Carmustine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Isradipine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00271</drugbank-id>
      <name>Diatrizoate</name>
      <description>Diatrizoate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>Liothyronine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Disopyramide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>Acarbose may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>Atomoxetine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>Bleomycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>Etomidate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>Etonogestrel may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>Ropivacaine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00303</drugbank-id>
      <name>Ertapenem</name>
      <description>Ertapenem may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>Ibutilide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>Piperacillin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>Floxuridine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>Tolcapone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Nitroprusside may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00330</drugbank-id>
      <name>Ethambutol</name>
      <description>Ethambutol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>Metformin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>Methadone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00339</drugbank-id>
      <name>Pyrazinamide</name>
      <description>Pyrazinamide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>Megestrol acetate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00355</drugbank-id>
      <name>Aztreonam</name>
      <description>Aztreonam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>Chlorzoxazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>Sulfadiazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00364</drugbank-id>
      <name>Sucralfate</name>
      <description>Sucralfate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Thiethylperazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>Palonosetron may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>Dexrazoxane may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>Eszopiclone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>Pramipexole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00415</drugbank-id>
      <name>Ampicillin</name>
      <description>Ampicillin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>Secobarbital may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>Methylphenidate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>Trifluridine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>Nitric Oxide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>Allopurinol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>Gemcitabine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>Duloxetine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>Fosinopril may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>Flutamide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Metolazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>Cefdinir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00548</drugbank-id>
      <name>Azelaic acid</name>
      <description>Azelaic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>Pentostatin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00553</drugbank-id>
      <name>Methoxsalen</name>
      <description>Methoxsalen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00558</drugbank-id>
      <name>Zanamivir</name>
      <description>Zanamivir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>Fondaparinux may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00583</drugbank-id>
      <name>Levocarnitine</name>
      <description>Levocarnitine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>Fluocinolone acetonide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00597</drugbank-id>
      <name>Gadoteridol</name>
      <description>Gadoteridol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Labetalol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>Medroxyprogesterone acetate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Bisoprolol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Testosterone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>Clorazepic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Clofarabine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>Dexmedetomidine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>Dyphylline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Mecamylamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>Metaxalone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>Nilutamide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>Galantamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>Flurazepam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>Phentolamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Furosemide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Nitrofurantoin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>Tamsulosin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00713</drugbank-id>
      <name>Oxacillin</name>
      <description>Oxacillin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00716</drugbank-id>
      <name>Nedocromil</name>
      <description>Nedocromil may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>Lisinopril may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>Thiabendazole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00733</drugbank-id>
      <name>Pralidoxime</name>
      <description>Pralidoxime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>Gadobenic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00760</drugbank-id>
      <name>Meropenem</name>
      <description>Meropenem may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00761</drugbank-id>
      <name>Potassium chloride</name>
      <description>Potassium chloride may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>Propantheline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00789</drugbank-id>
      <name>Gadopentetic acid</name>
      <description>Gadopentetic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>Perindopril may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>Fenoldopam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>Dicyclomine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Indapamide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>Ribavirin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00828</drugbank-id>
      <name>Fosfomycin</name>
      <description>Fosfomycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>Dobutamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>Oxazepam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>Dacarbazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>Temozolomide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>Terbutaline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00894</drugbank-id>
      <name>Testolactone</name>
      <description>Testolactone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Didanosine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>Zonisamide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00911</drugbank-id>
      <name>Tinidazole</name>
      <description>Tinidazole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>Amantadine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>Almotriptan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>Azacitidine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>Maprotiline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>Isoniazid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>Rizatriptan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Pindolol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00961</drugbank-id>
      <name>Mepivacaine</name>
      <description>Mepivacaine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>Zaleplon may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>Dopamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>Azathioprine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00995</drugbank-id>
      <name>Auranofin</name>
      <description>Auranofin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>Salbutamol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>Levobupivacaine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01010</drugbank-id>
      <name>Edrophonium</name>
      <description>Edrophonium may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01011</drugbank-id>
      <name>Metyrapone</name>
      <description>Metyrapone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>Guanfacine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide mononitrate</name>
      <description>Isosorbide mononitrate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01022</drugbank-id>
      <name>Phylloquinone</name>
      <description>Phylloquinone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Mycophenolic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>Fenofibrate may decrease the excretion rate of Memantine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>Fenofibrate may decrease the excretion rate of Lubiprostone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>Fenofibrate may decrease the excretion rate of Abacavir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01060</drugbank-id>
      <name>Amoxicillin</name>
      <description>Fenofibrate may decrease the excretion rate of Amoxicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>Fenofibrate may decrease the excretion rate of Clonazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Fenofibrate may decrease the excretion rate of Promethazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01093</drugbank-id>
      <name>Dimethyl sulfoxide</name>
      <description>Fenofibrate may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>Fenofibrate may decrease the excretion rate of Flucytosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>Fenofibrate may decrease the excretion rate of Capecitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>Fenofibrate may decrease the excretion rate of Sibutramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>Fenofibrate may decrease the excretion rate of Rabeprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>Fenofibrate may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>Fenofibrate may decrease the excretion rate of Doxacurium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>Fenofibrate may decrease the excretion rate of Flavoxate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01157</drugbank-id>
      <name>Trimetrexate</name>
      <description>Fenofibrate may decrease the excretion rate of Trimetrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>Fenofibrate may decrease the excretion rate of Guanethidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>Fenofibrate may decrease the excretion rate of Ifosfamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01205</drugbank-id>
      <name>Flumazenil</name>
      <description>Fenofibrate may decrease the excretion rate of Flumazenil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01213</drugbank-id>
      <name>Fomepizole</name>
      <description>Fenofibrate may decrease the excretion rate of Fomepizole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>Fenofibrate may decrease the excretion rate of Estazolam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>Fenofibrate may decrease the excretion rate of Ketamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Fenofibrate may decrease the excretion rate of Epoprostenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01249</drugbank-id>
      <name>Iodixanol</name>
      <description>Fenofibrate may decrease the excretion rate of Iodixanol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01273</drugbank-id>
      <name>Varenicline</name>
      <description>Fenofibrate may decrease the excretion rate of Varenicline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Fenofibrate may decrease the excretion rate of Hydralazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Fenofibrate may decrease the excretion rate of Penbutolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Fenofibrate may decrease the excretion rate of Rasagiline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>Fenofibrate may decrease the excretion rate of Tiotropium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01427</drugbank-id>
      <name>Amrinone</name>
      <description>Fenofibrate may decrease the excretion rate of Amrinone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01428</drugbank-id>
      <name>Oxybenzone</name>
      <description>Fenofibrate may decrease the excretion rate of Oxybenzone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>Fenofibrate may decrease the excretion rate of Allylestrenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01550</drugbank-id>
      <name>Fenproporex</name>
      <description>Fenofibrate may decrease the excretion rate of Fenproporex which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>Fenofibrate may decrease the excretion rate of Bromazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>Fenofibrate may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>Fenofibrate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01610</drugbank-id>
      <name>Valganciclovir</name>
      <description>Fenofibrate may decrease the excretion rate of Valganciclovir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>Fenofibrate may decrease the excretion rate of Sorbitol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Fenofibrate may decrease the excretion rate of Roflumilast which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>Fenofibrate may decrease the excretion rate of Topiroxostat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>Fenofibrate may decrease the excretion rate of Lorcaserin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>Fenofibrate may decrease the excretion rate of Pegaptanib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>Fenofibrate may decrease the excretion rate of Milnacipran which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Fenofibrate may decrease the excretion rate of Clevidipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>Fenofibrate may decrease the excretion rate of Lofexidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>Fenofibrate may decrease the excretion rate of Ezogabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05018</drugbank-id>
      <name>Migalastat</name>
      <description>Fenofibrate may decrease the excretion rate of Migalastat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06154</drugbank-id>
      <name>Pentaerythritol tetranitrate</name>
      <description>Fenofibrate may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>Fenofibrate may decrease the excretion rate of Ipilimumab which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>Fenofibrate may decrease the excretion rate of Icatibant which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Fenofibrate may decrease the excretion rate of Alogliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06211</drugbank-id>
      <name>Doripenem</name>
      <description>Fenofibrate may decrease the excretion rate of Doripenem which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06230</drugbank-id>
      <name>Nalmefene</name>
      <description>Fenofibrate may decrease the excretion rate of Nalmefene which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>Fenofibrate may decrease the excretion rate of Droxidopa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>Fenofibrate may decrease the excretion rate of Levocetirizine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Fenofibrate may decrease the excretion rate of Saxagliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>Fenofibrate may decrease the excretion rate of Telavancin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06623</drugbank-id>
      <name>Flupirtine</name>
      <description>Fenofibrate may decrease the excretion rate of Flupirtine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06637</drugbank-id>
      <name>Dalfampridine</name>
      <description>Fenofibrate may decrease the excretion rate of Dalfampridine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>Fenofibrate may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06705</drugbank-id>
      <name>Gadofosveset trisodium</name>
      <description>Fenofibrate may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>Fenofibrate may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06767</drugbank-id>
      <name>Ammonium chloride</name>
      <description>Fenofibrate may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06782</drugbank-id>
      <name>Dimercaprol</name>
      <description>Fenofibrate may decrease the excretion rate of Dimercaprol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06796</drugbank-id>
      <name>Mangafodipir</name>
      <description>Fenofibrate may decrease the excretion rate of Mangafodipir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06800</drugbank-id>
      <name>Methylnaltrexone</name>
      <description>Fenofibrate may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06809</drugbank-id>
      <name>Plerixafor</name>
      <description>Fenofibrate may decrease the excretion rate of Plerixafor which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>Fenofibrate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06823</drugbank-id>
      <name>Tiopronin</name>
      <description>Fenofibrate may decrease the excretion rate of Tiopronin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06824</drugbank-id>
      <name>Triethylenetetramine</name>
      <description>Fenofibrate may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08824</drugbank-id>
      <name>Ioflupane I-123</name>
      <description>Fenofibrate may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08826</drugbank-id>
      <name>Deferiprone</name>
      <description>Fenofibrate may decrease the excretion rate of Deferiprone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08840</drugbank-id>
      <name>N-methylnicotinamide</name>
      <description>Fenofibrate may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>Fenofibrate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>Fenofibrate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>Fenofibrate may decrease the excretion rate of Peginesatide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>Fenofibrate may decrease the excretion rate of Aclidinium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08900</drugbank-id>
      <name>Teduglutide</name>
      <description>Fenofibrate may decrease the excretion rate of Teduglutide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>Fenofibrate may decrease the excretion rate of Formestane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>Fenofibrate may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>Fenofibrate may decrease the excretion rate of Trametinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>Fenofibrate may decrease the excretion rate of Macitentan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08964</drugbank-id>
      <name>Gemeprost</name>
      <description>Fenofibrate may decrease the excretion rate of Gemeprost which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Fenofibrate may decrease the excretion rate of Empagliflozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09050</drugbank-id>
      <name>Ceftolozane</name>
      <description>Fenofibrate may decrease the excretion rate of Ceftolozane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09066</drugbank-id>
      <name>Corifollitropin alfa</name>
      <description>Fenofibrate may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>Fenofibrate may decrease the excretion rate of Tasimelteon which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09081</drugbank-id>
      <name>Idebenone</name>
      <description>Fenofibrate may decrease the excretion rate of Idebenone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>Fenofibrate may decrease the excretion rate of Vilanterol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>Fenofibrate may decrease the excretion rate of Trimebutine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>Fenofibrate may decrease the excretion rate of Tixocortol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09103</drugbank-id>
      <name>Ancestim</name>
      <description>Fenofibrate may decrease the excretion rate of Ancestim which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>Fenofibrate may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09106</drugbank-id>
      <name>Hydroxyethyl Starch</name>
      <description>Fenofibrate may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09111</drugbank-id>
      <name>Pentastarch</name>
      <description>Fenofibrate may decrease the excretion rate of Pentastarch which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09121</drugbank-id>
      <name>Aurothioglucose</name>
      <description>Fenofibrate may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>Fenofibrate may decrease the excretion rate of Dienogest which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09129</drugbank-id>
      <name>Chromic chloride</name>
      <description>Fenofibrate may decrease the excretion rate of Chromic chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09132</drugbank-id>
      <name>Gadoteric acid</name>
      <description>Fenofibrate may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09133</drugbank-id>
      <name>Iothalamic acid</name>
      <description>Fenofibrate may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09134</drugbank-id>
      <name>Ioversol</name>
      <description>Fenofibrate may decrease the excretion rate of Ioversol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09135</drugbank-id>
      <name>Ioxilan</name>
      <description>Fenofibrate may decrease the excretion rate of Ioxilan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09136</drugbank-id>
      <name>Isosulfan blue</name>
      <description>Fenofibrate may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09137</drugbank-id>
      <name>Technetium Tc-99m mebrofenin</name>
      <description>Fenofibrate may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>Fenofibrate may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09148</drugbank-id>
      <name>Florbetaben (18F)</name>
      <description>Fenofibrate may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09149</drugbank-id>
      <name>Florbetapir (18F)</name>
      <description>Fenofibrate may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09156</drugbank-id>
      <name>Iopromide</name>
      <description>Fenofibrate may decrease the excretion rate of Iopromide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09163</drugbank-id>
      <name>Technetium Tc-99m exametazime</name>
      <description>Fenofibrate may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09164</drugbank-id>
      <name>Technetium Tc-99m disofenin</name>
      <description>Fenofibrate may decrease the excretion rate of Technetium Tc-99m disofenin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09165</drugbank-id>
      <name>Technetium Tc-99m pyrophosphate</name>
      <description>Fenofibrate may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>Fenofibrate may decrease the excretion rate of Viloxazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>Fenofibrate may decrease the excretion rate of Etoperidone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>Fenofibrate may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Fenofibrate may decrease the excretion rate of Arotinolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>Fenofibrate may decrease the excretion rate of Moxisylyte which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09209</drugbank-id>
      <name>Pholcodine</name>
      <description>Fenofibrate may decrease the excretion rate of Pholcodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09210</drugbank-id>
      <name>Piracetam</name>
      <description>Fenofibrate may decrease the excretion rate of Piracetam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>Fenofibrate may decrease the excretion rate of Bisoxatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Fenofibrate may decrease the excretion rate of Nicorandil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>Fenofibrate may decrease the excretion rate of Blonanserin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>Fenofibrate may decrease the excretion rate of Melperone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Fenofibrate may decrease the excretion rate of Methylene blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Fenofibrate may decrease the excretion rate of Pirlindole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Fenofibrate may decrease the excretion rate of Toloxatone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Fenofibrate may decrease the excretion rate of Dextran which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>Fenofibrate may decrease the excretion rate of Tegafur which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09257</drugbank-id>
      <name>Gimeracil</name>
      <description>Fenofibrate may decrease the excretion rate of Gimeracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>Fenofibrate may decrease the excretion rate of Imidafenacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>Fenofibrate may decrease the excretion rate of Idarucizumab which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>Fenofibrate may decrease the excretion rate of Lixisenatide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>Fenofibrate may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09277</drugbank-id>
      <name>Choline C 11</name>
      <description>Fenofibrate may decrease the excretion rate of Choline C 11 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>Fenofibrate may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>Fenofibrate may decrease the excretion rate of Sacubitril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09301</drugbank-id>
      <name>Chondroitin sulfate</name>
      <description>Fenofibrate may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Fenofibrate may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Fenofibrate may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09320</drugbank-id>
      <name>Procaine benzylpenicillin</name>
      <description>Fenofibrate may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09324</drugbank-id>
      <name>Sulbactam</name>
      <description>Fenofibrate may decrease the excretion rate of Sulbactam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09325</drugbank-id>
      <name>Sodium fluoride</name>
      <description>Fenofibrate may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>Fenofibrate may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09338</drugbank-id>
      <name>Mersalyl</name>
      <description>Fenofibrate may decrease the excretion rate of Mersalyl which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09344</drugbank-id>
      <name>Invert sugar</name>
      <description>Fenofibrate may decrease the excretion rate of Invert sugar which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09357</drugbank-id>
      <name>Dexpanthenol</name>
      <description>Fenofibrate may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09394</drugbank-id>
      <name>Phosphoric acid</name>
      <description>Fenofibrate may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09395</drugbank-id>
      <name>Sodium acetate</name>
      <description>Fenofibrate may decrease the excretion rate of Sodium acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>Fenofibrate may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>Fenofibrate may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09472</drugbank-id>
      <name>Sodium sulfate</name>
      <description>Fenofibrate may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>Fenofibrate may decrease the excretion rate of Enalaprilat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>Fenofibrate may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09488</drugbank-id>
      <name>Acrivastine</name>
      <description>Fenofibrate may decrease the excretion rate of Acrivastine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09496</drugbank-id>
      <name>Octinoxate</name>
      <description>Fenofibrate may decrease the excretion rate of Octinoxate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09502</drugbank-id>
      <name>Fludeoxyglucose (18F)</name>
      <description>Fenofibrate may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09546</drugbank-id>
      <name>Iobenguane sulfate I-123</name>
      <description>Fenofibrate may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>Fenofibrate may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11090</drugbank-id>
      <name>Potassium nitrate</name>
      <description>Fenofibrate may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11098</drugbank-id>
      <name>Potassium bicarbonate</name>
      <description>Fenofibrate may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11102</drugbank-id>
      <name>N-acetyltyrosine</name>
      <description>Fenofibrate may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11114</drugbank-id>
      <name>Eucalyptus oil</name>
      <description>Fenofibrate may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11127</drugbank-id>
      <name>Selenious acid</name>
      <description>Fenofibrate may decrease the excretion rate of Selenious acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>Fenofibrate may decrease the excretion rate of Opium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11135</drugbank-id>
      <name>Selenium</name>
      <description>Fenofibrate may decrease the excretion rate of Selenium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11136</drugbank-id>
      <name>Chromium</name>
      <description>Fenofibrate may decrease the excretion rate of Chromium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11145</drugbank-id>
      <name>Oxyquinoline</name>
      <description>Fenofibrate may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>Fenofibrate may decrease the excretion rate of Pyrantel which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11164</drugbank-id>
      <name>Bicisate</name>
      <description>Fenofibrate may decrease the excretion rate of Bicisate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11251</drugbank-id>
      <name>Tocopherol</name>
      <description>Fenofibrate may decrease the excretion rate of Tocopherol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11278</drugbank-id>
      <name>DL-Methylephedrine</name>
      <description>Fenofibrate may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11328</drugbank-id>
      <name>Tetradecyl hydrogen sulfate (ester)</name>
      <description>Fenofibrate may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11338</drugbank-id>
      <name>Clove oil</name>
      <description>Fenofibrate may decrease the excretion rate of Clove oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>Fenofibrate may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11364</drugbank-id>
      <name>Pidotimod</name>
      <description>Fenofibrate may decrease the excretion rate of Pidotimod which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11577</drugbank-id>
      <name>Indigotindisulfonic acid</name>
      <description>Fenofibrate may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>Fenofibrate may decrease the excretion rate of Etafedrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Fenofibrate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11691</drugbank-id>
      <name>Naldemedine</name>
      <description>Fenofibrate may decrease the excretion rate of Naldemedine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11699</drugbank-id>
      <name>Tropisetron</name>
      <description>Fenofibrate may decrease the excretion rate of Tropisetron which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11915</drugbank-id>
      <name>Valbenazine</name>
      <description>Fenofibrate may decrease the excretion rate of Valbenazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Fenofibrate may decrease the excretion rate of Delafloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11989</drugbank-id>
      <name>Benznidazole</name>
      <description>Fenofibrate may decrease the excretion rate of Benznidazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12007</drugbank-id>
      <name>Isoflavone</name>
      <description>Fenofibrate may decrease the excretion rate of Isoflavone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12107</drugbank-id>
      <name>Vaborbactam</name>
      <description>Fenofibrate may decrease the excretion rate of Vaborbactam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>Fenofibrate may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Fenofibrate may decrease the excretion rate of Propiverine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12783</drugbank-id>
      <name>Benserazide</name>
      <description>Fenofibrate may decrease the excretion rate of Benserazide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>Fenofibrate may decrease the excretion rate of Tiapride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>Fenofibrate may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13145</drugbank-id>
      <name>Nedaplatin</name>
      <description>Fenofibrate may decrease the excretion rate of Nedaplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13156</drugbank-id>
      <name>Inosine pranobex</name>
      <description>Fenofibrate may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13178</drugbank-id>
      <name>Inositol</name>
      <description>Fenofibrate may decrease the excretion rate of Inositol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13185</drugbank-id>
      <name>Oxabolone cipionate</name>
      <description>Fenofibrate may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13191</drugbank-id>
      <name>Phosphocreatine</name>
      <description>Fenofibrate may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13269</drugbank-id>
      <name>Dichlorobenzyl alcohol</name>
      <description>Fenofibrate may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>Fenofibrate may decrease the excretion rate of Almasilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13884</drugbank-id>
      <name>Albutrepenonacog alfa</name>
      <description>Fenofibrate may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Fenofibrate may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>Fenofibrate may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>Fenofibrate may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>Fenofibrate may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>Fenofibrate may decrease the excretion rate of Patent Blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>Fenofibrate may decrease the excretion rate of Choline salicylate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14007</drugbank-id>
      <name>Pentetic acid</name>
      <description>Fenofibrate may decrease the excretion rate of Pentetic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14184</drugbank-id>
      <name>Cinnamaldehyde</name>
      <description>Fenofibrate may decrease the excretion rate of Cinnamaldehyde which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14186</drugbank-id>
      <name>Cinnamyl alcohol</name>
      <description>Fenofibrate may decrease the excretion rate of Cinnamyl alcohol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14498</drugbank-id>
      <name>Potassium acetate</name>
      <description>Fenofibrate may decrease the excretion rate of Potassium acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>Fenofibrate may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14526</drugbank-id>
      <name>Chromic citrate</name>
      <description>Fenofibrate may decrease the excretion rate of Chromic citrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14527</drugbank-id>
      <name>Chromic nitrate</name>
      <description>Fenofibrate may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14528</drugbank-id>
      <name>Chromium gluconate</name>
      <description>Fenofibrate may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14529</drugbank-id>
      <name>Chromium nicotinate</name>
      <description>Fenofibrate may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14530</drugbank-id>
      <name>Chromous sulfate</name>
      <description>Fenofibrate may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>Fenofibrate may decrease the excretion rate of Solriamfetol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06815</drugbank-id>
      <name>Pyrithione</name>
      <description>Fenofibrate may decrease the excretion rate of Pyrithione which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11121</drugbank-id>
      <name>Chloroxylenol</name>
      <description>Fenofibrate may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>Temazepam may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09276</drugbank-id>
      <name>Sodium aurothiomalate</name>
      <description>Fenofibrate may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11085</drugbank-id>
      <name>Resorcinol</name>
      <description>Fenofibrate may decrease the excretion rate of Resorcinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15593</drugbank-id>
      <name>Golodirsen</name>
      <description>Fenofibrate may decrease the excretion rate of Golodirsen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>Fenofibrate may decrease the excretion rate of Capreomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>Fenofibrate may decrease the excretion rate of Codeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>Fenofibrate may decrease the excretion rate of Vancomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>Fenofibrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>Fenofibrate may decrease the excretion rate of Pemetrexed which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00879</drugbank-id>
      <name>Emtricitabine</name>
      <description>Fenofibrate may decrease the excretion rate of Emtricitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>Fenofibrate may decrease the excretion rate of Isotretinoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>Fenofibrate may decrease the excretion rate of Procainamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Fenofibrate may decrease the excretion rate of Desipramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Fenofibrate may decrease the excretion rate of Lithium cation which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Fenofibrate may decrease the excretion rate of Dimetacrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>Fenofibrate may decrease the excretion rate of Plazomicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>Fenofibrate may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>Fenofibrate may decrease the excretion rate of Lithium citrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14508</drugbank-id>
      <name>Lithium succinate</name>
      <description>Fenofibrate may decrease the excretion rate of Lithium succinate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>Fenofibrate may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Spironolactone may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Methyclothiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Chlorthalidone may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>Ethoxzolamide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Bendroflumethiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>Benzthiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>Amiloride may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>Cyclothiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Hydroflumethiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Chlorothiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Trichlormethiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Diazoxide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>Diclofenamide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Polythiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>Quinethazone may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>Theobromine may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>Piretanide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>Tienilic acid may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05034</drugbank-id>
      <name>Ularitide</name>
      <description>Ularitide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>Azosemide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09015</drugbank-id>
      <name>Canrenoic acid</name>
      <description>Canrenoic acid may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>Potassium citrate may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>Isosorbide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12221</drugbank-id>
      <name>Canrenone</name>
      <description>Canrenone may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12670</drugbank-id>
      <name>Rolofylline</name>
      <description>Rolofylline may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12704</drugbank-id>
      <name>Spiradoline</name>
      <description>Spiradoline may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>Cicletanine may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>Meticrane may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>Ibopamine may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>Mefruside may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>Mebutizide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Cyclopenthiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>Clorexolone may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>Clofenamide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>Fenquizone may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>Clopamide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>Muzolimine may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>Xipamide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>Epitizide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>Bromotheophylline may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14500</drugbank-id>
      <name>Potassium</name>
      <description>Potassium may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>Methazolamide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00052</drugbank-id>
      <name>Somatotropin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00080</drugbank-id>
      <name>Daptomycin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00471</drugbank-id>
      <name>Montelukast</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00666</drugbank-id>
      <name>Nafarelin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Terbinafine is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Penicillamine is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ethanol is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01006</drugbank-id>
      <name>Letrozole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06817</drugbank-id>
      <name>Raltegravir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Raltegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09055</drugbank-id>
      <name>Acipimox</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Acipimox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Ipecac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13393</drugbank-id>
      <name>Emetine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Emetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00615</drugbank-id>
      <name>Rifabutin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Rifabutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Felbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04911</drugbank-id>
      <name>Oritavancin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Oritavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Rufinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06413</drugbank-id>
      <name>Armodafinil</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Armodafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Eslicarbazepine acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The metabolism of Sulfinpyrazone can be increased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Pegvisomant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00136</drugbank-id>
      <name>Calcitriol</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Calcitriol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Butalbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00301</drugbank-id>
      <name>Flucloxacillin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Flucloxacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00357</drugbank-id>
      <name>Aminoglutethimide</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Aminoglutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00400</drugbank-id>
      <name>Griseofulvin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Griseofulvin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Methohexital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00485</drugbank-id>
      <name>Dicloxacillin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Dicloxacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Ethotoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00769</drugbank-id>
      <name>Hydrocortamate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Hydrocortamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Methylphenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Norgestimate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01083</drugbank-id>
      <name>Orlistat</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Orlistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01201</drugbank-id>
      <name>Rifapentine</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Rifapentine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Amobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Aprobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Barbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Tesmilifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06636</drugbank-id>
      <name>Isavuconazonium</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Isavuconazonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06708</drugbank-id>
      <name>Lumefantrine</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Lumefantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Perampanel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Barbexaclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Brigatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00163</drugbank-id>
      <name>Vitamin E</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Vitamin E.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Eslicarbazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01369</drugbank-id>
      <name>Quinupristin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Quinupristin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01764</drugbank-id>
      <name>Dalfopristin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Dalfopristin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04794</drugbank-id>
      <name>Bifonazole</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Bifonazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04894</drugbank-id>
      <name>Vapreotide</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Vapreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Pasireotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Lanreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11703</drugbank-id>
      <name>Acalabrutinib</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Acalabrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Mirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00778</drugbank-id>
      <name>Roxithromycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Roxithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01128</drugbank-id>
      <name>Bicalutamide</name>
      <description>The metabolism of Bicalutamide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The metabolism of Orphenadrine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The metabolism of Cyproterone acetate can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The metabolism of Dapoxetine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08820</drugbank-id>
      <name>Ivacaftor</name>
      <description>The metabolism of Ivacaftor can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The metabolism of Manidipine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00353</drugbank-id>
      <name>Methylergometrine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Methylergometrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Dextropropoxyphene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Tranylcypromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Acetazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Metronidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00954</drugbank-id>
      <name>Dirithromycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Dirithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01071</drugbank-id>
      <name>Mequitazine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Mequitazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01085</drugbank-id>
      <name>Pilocarpine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Pilocarpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01152</drugbank-id>
      <name>Candicidin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Candicidin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Pergolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01698</drugbank-id>
      <name>Rutin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Rutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01873</drugbank-id>
      <name>Epothilone D</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Epothilone D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Resveratrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03010</drugbank-id>
      <name>Patupilone</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Patupilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04070</drugbank-id>
      <name>6-Deoxyerythronolide B</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with 6-Deoxyerythronolide B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05482</drugbank-id>
      <name>7-ethyl-10-hydroxycamptothecin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05814</drugbank-id>
      <name>GPI-1485</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with GPI-1485.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05903</drugbank-id>
      <name>KOS-1584</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with KOS-1584.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06174</drugbank-id>
      <name>Noscapine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Noscapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06233</drugbank-id>
      <name>Ridaforolimus</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Ridaforolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06318</drugbank-id>
      <name>AVE9633</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with AVE9633.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06342</drugbank-id>
      <name>Coltuximab ravtansine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Coltuximab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06412</drugbank-id>
      <name>Oxymetholone</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Oxymetholone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06419</drugbank-id>
      <name>Cethromycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Cethromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Remacemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06469</drugbank-id>
      <name>Lestaurtinib</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Lestaurtinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06587</drugbank-id>
      <name>Mitemcinal</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Mitemcinal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Capsaicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07348</drugbank-id>
      <name>Brefeldin A</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Brefeldin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08811</drugbank-id>
      <name>Tofisopam</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Tofisopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Efonidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09308</drugbank-id>
      <name>Solithromycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Solithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09309</drugbank-id>
      <name>Kitasamycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Kitasamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11198</drugbank-id>
      <name>Peppermint oil</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Peppermint oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11383</drugbank-id>
      <name>Carbomycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Carbomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Doramectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11405</drugbank-id>
      <name>Eprinomectin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Eprinomectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11442</drugbank-id>
      <name>Oleandomycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Oleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11459</drugbank-id>
      <name>Selamectin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Selamectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11470</drugbank-id>
      <name>Tildipirosin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Tildipirosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11471</drugbank-id>
      <name>Tilmicosin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Tilmicosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11475</drugbank-id>
      <name>Tylosin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Tylosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11554</drugbank-id>
      <name>Tylvalosin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Tylvalosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11752</drugbank-id>
      <name>Bryostatin 1</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Bryostatin 1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11805</drugbank-id>
      <name>Saracatinib</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Saracatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12089</drugbank-id>
      <name>Lorvotuzumab mertansine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Lorvotuzumab mertansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12266</drugbank-id>
      <name>Epofolate</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Epofolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12391</drugbank-id>
      <name>Sagopilone</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Sagopilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12489</drugbank-id>
      <name>Mirvetuximab Soravtansine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Mirvetuximab Soravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12532</drugbank-id>
      <name>Oxetacaine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Oxetacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12582</drugbank-id>
      <name>Piperine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Piperine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13287</drugbank-id>
      <name>Miocamycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Miocamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13338</drugbank-id>
      <name>Flurithromycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Flurithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13409</drugbank-id>
      <name>Rokitamycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Rokitamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13456</drugbank-id>
      <name>Midecamycin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Midecamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13633</drugbank-id>
      <name>Mepartricin</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Mepartricin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with WIN 55212-2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13975</drugbank-id>
      <name>Black cohosh</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Black cohosh.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Edetate disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14635</drugbank-id>
      <name>Curcumin sulfate</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Curcumin sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12010</drugbank-id>
      <name>Fostamatinib</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Fostamatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The metabolism of Sildenafil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00204</drugbank-id>
      <name>Dofetilide</name>
      <description>The metabolism of Dofetilide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The metabolism of Eletriptan can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The metabolism of Indinavir can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The metabolism of Lovastatin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>The metabolism of Methysergide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The metabolism of Dihydroergotamine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The metabolism of Nisoldipine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The metabolism of Alprazolam can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Zolpidem can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The metabolism of Levothyroxine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The metabolism of Meperidine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The metabolism of Buspirone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The metabolism of Darifenacin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The metabolism of Nortriptyline can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The metabolism of Ethosuximide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The metabolism of Cisapride can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The metabolism of Astemizole can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00673</drugbank-id>
      <name>Aprepitant</name>
      <description>The metabolism of Aprepitant can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The metabolism of Midazolam can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>The metabolism of Eplerenone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The metabolism of Alfentanil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The metabolism of Fentanyl can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>The metabolism of Tadalafil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The metabolism of Vardenafil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The metabolism of Triazolam can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The metabolism of Cyclobenzaprine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The metabolism of Busulfan can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The metabolism of Felodipine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The metabolism of Pimozide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>The metabolism of Clindamycin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The metabolism of Bromocriptine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The metabolism of Budesonide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The metabolism of Levacetylmethadol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The metabolism of Dasatinib can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The metabolism of 4-hydroxycoumarin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04835</drugbank-id>
      <name>Maraviroc</name>
      <description>The metabolism of Maraviroc can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The metabolism of Dronedarone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The metabolism of Tolvaptan can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The metabolism of Rivaroxaban can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06237</drugbank-id>
      <name>Avanafil</name>
      <description>The metabolism of Avanafil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06717</drugbank-id>
      <name>Fosaprepitant</name>
      <description>The metabolism of Fosaprepitant can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The metabolism of Ethyl biscoumacetate can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The metabolism of Lurasidone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The metabolism of Ticagrelor can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08827</drugbank-id>
      <name>Lomitapide</name>
      <description>The metabolism of Lomitapide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The metabolism of Rilpivirine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The metabolism of Eliglustat can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The metabolism of Ibrutinib can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The metabolism of Tianeptine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The metabolism of Isavuconazole can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11742</drugbank-id>
      <name>Ebastine</name>
      <description>The metabolism of Ebastine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The metabolism of Esketamine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The metabolism of Clorindione can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The metabolism of Diphenadione can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>The metabolism of Dihydroergocristine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Phentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00426</drugbank-id>
      <name>Famciclovir</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Famciclovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Prochlorperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Albendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Norethisterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01411</drugbank-id>
      <name>Pranlukast</name>
      <description>The metabolism of Pranlukast can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The metabolism of Zuclopenthixol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The metabolism of Vorapaxar can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>The metabolism of Suvorexant can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09274</drugbank-id>
      <name>Artesunate</name>
      <description>The metabolism of Artesunate can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11094</drugbank-id>
      <name>Vitamin D</name>
      <description>The metabolism of Vitamin D can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11273</drugbank-id>
      <name>Dihydroergocornine</name>
      <description>The metabolism of Dihydroergocornine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12515</drugbank-id>
      <name>9-aminocamptothecin</name>
      <description>The metabolism of 9-aminocamptothecin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12952</drugbank-id>
      <name>Methylprednisone</name>
      <description>The metabolism of Methylprednisone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13385</drugbank-id>
      <name>Dihydroergocryptine</name>
      <description>The metabolism of Dihydroergocryptine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The metabolism of Drospirenone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15444</drugbank-id>
      <name>Elexacaftor</name>
      <description>The metabolism of Elexacaftor can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Dacomitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The metabolism of Valsartan can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Nicotine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The metabolism of Bortezomib can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The metabolism of Torasemide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The metabolism of Dapsone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The metabolism of Bexarotene can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The metabolism of Hydromorphone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The metabolism of Trimethadione can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The metabolism of Treprostinil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The metabolism of Rosiglitazone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The metabolism of Promazine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>The metabolism of Dronabinol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The metabolism of Fluoxetine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The metabolism of Dextromethorphan can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The metabolism of Cyclophosphamide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Mephenytoin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00549</drugbank-id>
      <name>Zafirlukast</name>
      <description>The metabolism of Zafirlukast can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The metabolism of Cinnarizine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The metabolism of Doxazosin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The metabolism of Paramethadione can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The metabolism of Nateglinide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The metabolism of Zileuton can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The metabolism of Tretinoin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The metabolism of Candesartan cilexetil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The metabolism of Donepezil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The metabolism of Buprenorphine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The metabolism of Alosetron can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The metabolism of Azelastine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The metabolism of Ramelteon can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The metabolism of Formoterol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The metabolism of Methoxyflurane can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The metabolism of Irbesartan can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The metabolism of Tolterodine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The metabolism of Selegiline can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The metabolism of Thalidomide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The metabolism of Melatonin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The metabolism of Diphenhydramine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The metabolism of Sertraline can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The metabolism of Proguanil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The metabolism of Pioglitazone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The metabolism of Carvedilol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The metabolism of Thiamylal can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The metabolism of Bupropion can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The metabolism of Halothane can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The metabolism of Moclobemide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The metabolism of Idarubicin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The metabolism of Zopiclone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The metabolism of Arformoterol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The metabolism of Hexobarbital can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The metabolism of Mestranol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>The metabolism of Quazepam can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03756</drugbank-id>
      <name>Doconexent</name>
      <description>The metabolism of Doconexent can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Phenacetin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04557</drugbank-id>
      <name>Arachidonic Acid</name>
      <description>The metabolism of Arachidonic Acid can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The metabolism of Estrone sulfate can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The metabolism of Licofelone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The metabolism of Flunarizine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The metabolism of Ximelagatran can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04938</drugbank-id>
      <name>Ospemifene</name>
      <description>The metabolism of Ospemifene can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The metabolism of Brivaracetam can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The metabolism of Tapentadol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The metabolism of Prasugrel can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The metabolism of Lacosamide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>The metabolism of Sitaxentan can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The metabolism of Indisulam can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The metabolism of Etravirine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06652</drugbank-id>
      <name>Vicriviroc</name>
      <description>The metabolism of Vicriviroc can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The metabolism of Artemether can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The metabolism of Ketobemidone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The metabolism of Seratrodast can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06803</drugbank-id>
      <name>Niclosamide</name>
      <description>The metabolism of Niclosamide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The metabolism of Tranilast can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08875</drugbank-id>
      <name>Cabozantinib</name>
      <description>The metabolism of Cabozantinib can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The metabolism of Netupitant can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The metabolism of Cannabidiol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The metabolism of Vortioxetine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The metabolism of Olodaterol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The metabolism of Ixazomib can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11560</drugbank-id>
      <name>Lesinurad</name>
      <description>The metabolism of Lesinurad can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11614</drugbank-id>
      <name>Rupatadine</name>
      <description>The metabolism of Rupatadine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Triclabendazole can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The metabolism of Lynestrenol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The metabolism of Candesartan can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13941</drugbank-id>
      <name>Piperaquine</name>
      <description>The metabolism of Piperaquine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The metabolism of Medical Cannabis can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The metabolism of Nabiximols can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Nevirapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The metabolism of Flurbiprofen can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The metabolism of Desogestrel can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The metabolism of Flunitrazepam can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14975</drugbank-id>
      <name>Voxelotor</name>
      <description>The metabolism of Voxelotor can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The metabolism of Dicoumarol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The metabolism of Valproic acid can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Acenocoumarol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The metabolism of Siponimod can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The metabolism of Fluindione can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The therapeutic efficacy of Fenofibrate can be decreased when used in combination with Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The serum concentration of Afatinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The serum concentration of Bosutinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The serum concentration of Brentuximab vedotin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The serum concentration of Colchicine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The serum concentration of Edoxaban can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>The serum concentration of Ledipasvir can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09049</drugbank-id>
      <name>Naloxegol</name>
      <description>The serum concentration of Naloxegol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The serum concentration of Pazopanib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The serum concentration of Prucalopride can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The serum concentration of Ranolazine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The serum concentration of Silodosin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The serum concentration of Topotecan can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The serum concentration of Everolimus can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01220</drugbank-id>
      <name>Rifaximin</name>
      <description>The serum concentration of Rifaximin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The excretion of Vincristine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The serum concentration of Doxorubicin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The serum concentration of Betrixaban can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The serum concentration of Amitriptyline can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The serum concentration of Imipramine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Carbamazepine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The serum concentration of Clonidine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The serum concentration of Sirolimus can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The serum concentration of Quinidine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The serum concentration of Rifampicin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Phenobarbital can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The serum concentration of Paclitaxel can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The serum concentration of Digitoxin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The serum concentration of Temsirolimus can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Fenofibrate may decrease the excretion rate of Digoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>Fenofibrate may decrease the excretion rate of Metildigoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>Fenofibrate may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12825</drugbank-id>
      <name>Lefamulin</name>
      <description>Fenofibrate may decrease the excretion rate of Lefamulin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00027</drugbank-id>
      <name>Gramicidin D</name>
      <description>The serum concentration of Gramicidin D can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The serum concentration of Octreotide can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00126</drugbank-id>
      <name>Ascorbic acid</name>
      <description>The serum concentration of Ascorbic acid can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The serum concentration of Tramadol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The serum concentration of Erythromycin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The serum concentration of Azithromycin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The serum concentration of Pantoprazole can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Cabergoline can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The serum concentration of Metoprolol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The serum concentration of Topiramate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The serum concentration of Venlafaxine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The serum concentration of Conjugated estrogens can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The serum concentration of Chlorambucil can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The serum concentration of Morphine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The serum concentration of Mitomycin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The serum concentration of Acetaminophen can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The serum concentration of Gefitinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The serum concentration of Indomethacin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The serum concentration of Olanzapine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The serum concentration of Omeprazole can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The serum concentration of Cetirizine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The serum concentration of Diltiazem can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The serum concentration of Clobazam can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The serum concentration of Mefloquine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The serum concentration of Vinorelbine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The serum concentration of Clozapine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The serum concentration of Grepafloxacin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The serum concentration of Timolol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The serum concentration of Amlodipine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The serum concentration of Tacrine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The serum concentration of Betamethasone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The serum concentration of Teniposide can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The serum concentration of Lansoprazole can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The serum concentration of Prazosin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The serum concentration of Quinine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The serum concentration of Lenalidomide can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>The serum concentration of Raloxifene can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Haloperidol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The serum concentration of Alitretinoin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The serum concentration of Ciprofloxacin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The serum concentration of Toremifene can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The serum concentration of Methotrexate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The serum concentration of Nizatidine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The serum concentration of Fluticasone propionate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The serum concentration of Ivermectin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The serum concentration of Chloroquine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The serum concentration of Imatinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The serum concentration of Nicardipine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The serum concentration of Prednisone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The serum concentration of Pentazocine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The serum concentration of Sumatriptan can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The serum concentration of Losartan can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The serum concentration of Mycophenolate mofetil can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The serum concentration of Daunorubicin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The serum concentration of Amprenavir can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The serum concentration of Lamivudine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The serum concentration of Esomeprazole can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The serum concentration of Hydrocortisone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The serum concentration of Mannitol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The serum concentration of Clopidogrel can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The serum concentration of Tetracycline can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The serum concentration of Irinotecan can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The serum concentration of Olopatadine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The serum concentration of Etoposide can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Estradiol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The serum concentration of Diazepam can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The serum concentration of Trifluoperazine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The serum concentration of Prednisolone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Ranitidine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The serum concentration of Flupentixol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00882</drugbank-id>
      <name>Clomifene</name>
      <description>The serum concentration of Clomifene can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The serum concentration of Ondansetron can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The serum concentration of Acetylsalicylic acid can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The serum concentration of Fexofenadine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The serum concentration of Methylprednisolone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The serum concentration of Dactinomycin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The serum concentration of Dipyridamole can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The serum concentration of Cytarabine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The serum concentration of Hydroxyurea can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The serum concentration of Melphalan can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The serum concentration of Ibuprofen can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The serum concentration of Atorvastatin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The serum concentration of Tegaserod can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The serum concentration of Nifedipine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The serum concentration of Levofloxacin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The serum concentration of Arsenic trioxide can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The serum concentration of Domperidone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The serum concentration of Acebutolol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The serum concentration of Levetiracetam can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The serum concentration of Nadolol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The serum concentration of Mitoxantrone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The serum concentration of Sparfloxacin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The serum concentration of Docetaxel can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The serum concentration of Sitagliptin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The serum concentration of Paliperidone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The serum concentration of Sunitinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The serum concentration of Vecuronium can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01400</drugbank-id>
      <name>Neostigmine</name>
      <description>The serum concentration of Neostigmine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The serum concentration of Ketazolam can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Stanolone</name>
      <description>The serum concentration of Stanolone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03203</drugbank-id>
      <name>Sphingosine</name>
      <description>The serum concentration of Sphingosine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03825</drugbank-id>
      <name>Rhodamine 6G</name>
      <description>The serum concentration of Rhodamine 6G can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>The serum concentration of Estriol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The serum concentration of Aldosterone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>The serum concentration of Camptothecin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The serum concentration of Debrisoquine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The serum concentration of Celiprolol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The serum concentration of Belinostat can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The serum concentration of Indacaterol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The serum concentration of Cobimetinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The serum concentration of Trastuzumab emtansine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The serum concentration of Romidepsin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The serum concentration of Dapagliflozin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The serum concentration of Ambrisentan can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The serum concentration of Panobinostat can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The serum concentration of Apixaban can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The serum concentration of Axitinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06670</drugbank-id>
      <name>Odanacatib</name>
      <description>The serum concentration of Odanacatib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of Fesoterodine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The serum concentration of Cabazitaxel can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The serum concentration of Crizotinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08874</drugbank-id>
      <name>Fidaxomicin</name>
      <description>The serum concentration of Fidaxomicin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Vemurafenib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Linagliptin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The serum concentration of Carfilzomib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The serum concentration of Mirabegron can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The serum concentration of Ponatinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The serum concentration of Fluticasone furoate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The serum concentration of Canagliflozin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The serum concentration of Pomalidomide can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The serum concentration of Dabrafenib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The serum concentration of Levomilnacipran can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>The serum concentration of Dolutegravir can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>The serum concentration of Sofosbuvir can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The serum concentration of Ceritinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The serum concentration of Palbociclib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The serum concentration of Olaparib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The serum concentration of Umeclidinium can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The serum concentration of Nintedanib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09099</drugbank-id>
      <name>Somatostatin</name>
      <description>The serum concentration of Somatostatin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09161</drugbank-id>
      <name>Technetium Tc-99m sestamibi</name>
      <description>The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The serum concentration of Ubidecarenone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The serum concentration of Osimertinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The serum concentration of Selexipag can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11431</drugbank-id>
      <name>Moxidectin</name>
      <description>The serum concentration of Moxidectin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11447</drugbank-id>
      <name>Phenothiazine</name>
      <description>The serum concentration of Phenothiazine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11574</drugbank-id>
      <name>Elbasvir</name>
      <description>The serum concentration of Elbasvir can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11575</drugbank-id>
      <name>Grazoprevir</name>
      <description>The serum concentration of Grazoprevir can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The serum concentration of Venetoclax can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The serum concentration of Asunaprevir can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>The serum concentration of Velpatasvir can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The serum concentration of Vinflunine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11712</drugbank-id>
      <name>Tezacaftor</name>
      <description>The serum concentration of Tezacaftor can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>The serum concentration of Talazoparib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The serum concentration of Talinolol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The serum concentration of Baricitinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The serum concentration of Revefenacin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11869</drugbank-id>
      <name>Valspodar</name>
      <description>The serum concentration of Valspodar can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>The serum concentration of Duvelisib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The serum concentration of Glasdegib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The serum concentration of Elagolix can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>The serum concentration of Avatrombopag can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The serum concentration of Abemaciclib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The serum concentration of Alpelisib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The serum concentration of Voxilaprevir can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The serum concentration of Gilteritinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The serum concentration of Erdafitinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The serum concentration of Bromperidol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The serum concentration of Omadacycline can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>The serum concentration of Copanlisib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12836</drugbank-id>
      <name>Grapiprant</name>
      <description>The serum concentration of Grapiprant can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13125</drugbank-id>
      <name>Lusutrombopag</name>
      <description>The serum concentration of Lusutrombopag can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13146</drugbank-id>
      <name>Fluciclovine (18F)</name>
      <description>The serum concentration of Fluciclovine (18F) can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13173</drugbank-id>
      <name>Cerliponase alfa</name>
      <description>The serum concentration of Cerliponase alfa can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The serum concentration of Fluticasone can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13951</drugbank-id>
      <name>Stanolone acetate</name>
      <description>The serum concentration of Stanolone acetate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The serum concentration of Estradiol acetate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The serum concentration of Estradiol benzoate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The serum concentration of Estradiol cypionate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The serum concentration of Estradiol dienanthate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The serum concentration of Estradiol valerate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The serum concentration of Ivosidenib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>The serum concentration of Larotrectinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The serum concentration of Fenofibrate can be increased when it is combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The serum concentration of Fenofibrate can be increased when it is combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The serum concentration of Fenofibrate can be increased when it is combined with Dasabuvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>The serum concentration of Fenofibrate can be increased when it is combined with Ombitasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>The serum concentration of Fenofibrate can be increased when it is combined with Paritaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The serum concentration of Fenofibrate can be increased when it is combined with Ertugliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The serum concentration of Fenofibrate can be increased when it is combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>The serum concentration of Fenofibrate can be increased when it is combined with Pibrentasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>The serum concentration of Fenofibrate can be increased when it is combined with Glecaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The serum concentration of Fenofibrate can be increased when it is combined with Loratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The serum concentration of Quetiapine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The serum concentration of Entrectinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The serum concentration of Fedratinib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The serum concentration of Nelfinavir can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The serum concentration of Zidovudine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The serum concentration of Lamotrigine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>The serum concentration of Testosterone propionate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The serum concentration of Oxcarbazepine can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The serum concentration of Flecainide can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The serum concentration of Anastrozole can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The serum concentration of Lasmiditan can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13007</drugbank-id>
      <name>Enfortumab vedotin</name>
      <description>The serum concentration of Enfortumab vedotin can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The serum concentration of Trastuzumab deruxtecan can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>The serum concentration of Darolutamide can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Metreleptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00613</drugbank-id>
      <name>Amodiaquine</name>
      <description>The metabolism of Amodiaquine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00799</drugbank-id>
      <name>Tazarotene</name>
      <description>The metabolism of Tazarotene can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The metabolism of Beraprost can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06510</drugbank-id>
      <name>Muraglitazar</name>
      <description>The metabolism of Muraglitazar can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The metabolism of Benzyl alcohol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The metabolism of Halofantrine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08502</drugbank-id>
      <name>Capravirine</name>
      <description>The metabolism of Capravirine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The metabolism of Perospirone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The metabolism of Riociguat can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The metabolism of Lobeglitazone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The metabolism of Netoglitazone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The metabolism of Rivoglitazone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The metabolism of Ciglitazone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The metabolism of Balaglitazone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The metabolism of Phenprocoumon can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Amiodarone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The metabolism of Lapatinib can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The metabolism of Lorlatinib can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>The metabolism of Carisoprodol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The metabolism of Thioridazine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Praziquantel can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The metabolism of Escitalopram can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The metabolism of Nebivolol can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The metabolism of Methsuximide can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>The metabolism of Dexlansoprazole can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The metabolism of Vilazodone can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The metabolism of Etizolam can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>The metabolism of Dexrabeprazole can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The metabolism of Fenofibrate can be decreased when combined with Thiopental.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Warfarin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Clomipramine can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09327</drugbank-id>
      <name>Tegafur-uracil</name>
      <description>The metabolism of Tegafur-uracil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The metabolism of Sevoflurane can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04977</drugbank-id>
      <name>Plitidepsin</name>
      <description>The metabolism of Plitidepsin can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The metabolism of Clomethiazole can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Eltrombopag can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The risk or severity of QTc prolongation can be increased when Fenofibrate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Propranolol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The serum concentration of Fenofibrate can be decreased when it is combined with Cenobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15328</drugbank-id>
      <name>Ubrogepant</name>
      <description>The serum concentration of Ubrogepant can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The serum concentration of Cilostazol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The serum concentration of Fenofibrate can be decreased when it is combined with Pitolisant.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.86</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>7.07e-04 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>5.28</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>antara</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>360.831</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>360.112836867</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C20H21ClO4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>YMTINGFKWWXKFG-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>52.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>97.13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>38.15</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-4.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>79-82</value>
      <source>FDA Label</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>5.2</value>
      <source>Wei et al, 2017</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>1381</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>5001</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>3339</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507371</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07586</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00565</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>3222</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50085042</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449594</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000270</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Fenofibrate</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL672</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/fenofibrate.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cx1550.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/fenofibrate.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01039</drugbank-id>
        <name>Fenofibrate</name>
      </left-element>
      <right-element>
        <drugbank-id>DB13873</drugbank-id>
        <name>Fenofibric acid</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002705</drugbank-id>
          <name>Liver carboxylesterase 1</name>
          <uniprot-id>P23141</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB13873</drugbank-id>
        <name>Fenofibric acid</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02797</drugbank-id>
        <name>Fenofibryl Glucuronide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0003538</drugbank-id>
          <name>UDP-glucuronosyltransferase 1-9</name>
          <uniprot-id>O60656</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB13873</drugbank-id>
        <name>Fenofibric acid</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02798</drugbank-id>
        <name>Reduced Fenofibric Acid</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0003074</drugbank-id>
          <name>Carbonyl reductase [NADPH] 1</name>
          <uniprot-id>P16152</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0000126</drugbank-id>
          <name>Aldo-keto reductase family 1 member C1</name>
          <uniprot-id>Q04828</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0000622</drugbank-id>
          <name>Aldo-keto reductase family 1 member C2</name>
          <uniprot-id>P52895</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0000592</drugbank-id>
          <name>Aldo-keto reductase family 1 member C3</name>
          <uniprot-id>P42330</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0000747</drugbank-id>
          <name>Aldose reductase</name>
          <uniprot-id>P15121</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>3</sequence>
      <left-element>
        <drugbank-id>DBMET02798</drugbank-id>
        <name>Reduced Fenofibric Acid</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02799</drugbank-id>
        <name>Reduced Fenofibric Acid Glucuronide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0003538</drugbank-id>
          <name>UDP-glucuronosyltransferase 1-9</name>
          <uniprot-id>O60656</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000071</id>
      <name>Peroxisome proliferator-activated receptor alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6170</ref-id>
            <pubmed-id>10494028</pubmed-id>
            <citation>Clavey V, Copin C, Mariotte MC, Bauge E, Chinetti G, Fruchart J, Fruchart JC, Dallongeville J, Staels B: Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem. 1999;9(3):139-49.</citation>
          </article>
          <article>
            <ref-id>A6171</ref-id>
            <pubmed-id>10799317</pubmed-id>
            <citation>Chaput E, Saladin R, Silvestre M, Edgar AD: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000 May 10;271(2):445-50.</citation>
          </article>
          <article>
            <ref-id>A6172</ref-id>
            <pubmed-id>11018525</pubmed-id>
            <citation>Casas F, Pineau T, Rochard P, Rodier A, Daury L, Dauca M, Cabello G, Wrutniak-Cabello C: New molecular aspects of regulation of mitochondrial activity by fenofibrate and fasting. FEBS Lett. 2000 Sep 29;482(1-2):71-4.</citation>
          </article>
          <article>
            <ref-id>A6173</ref-id>
            <pubmed-id>11342537</pubmed-id>
            <citation>Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart JC, Staels B, Lagrost L, Luc G: Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem. 2001 Jul 13;276(28):25841-7. Epub 2001 May 7.</citation>
          </article>
          <article>
            <ref-id>A6174</ref-id>
            <pubmed-id>11474486</pubmed-id>
            <citation>Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, Paterniti JR Jr: Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism. 2001 Aug;50(8):963-71.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A6175</ref-id>
            <pubmed-id>10828060</pubmed-id>
            <citation>Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q07869" source="Swiss-Prot">
        <name>Peroxisome proliferator-activated receptor alpha</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2.</specific-function>
        <gene-name>PPARA</gene-name>
        <locus>22q12-q13.1|22q13.31</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.2</theoretical-pi>
        <molecular-weight>52224.595</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9232</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PPARA</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L02932</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307341</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q07869</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PPARA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NR1C1</synonym>
          <synonym>Nuclear receptor subfamily 1 group C member 1</synonym>
          <synonym>PPAR</synonym>
          <synonym>PPAR-alpha</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000142|Peroxisome proliferator-activated receptor alpha
MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSC
PGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACE
GCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSE
KAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFV
IHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANL
DLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFD
FAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDI
FLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021925|Peroxisome proliferator-activated receptor alpha (PPARA)
ATGGTGGACACGGAAAGCCCACTCTGCCCCCTCTCCCCACTCGAGGCCGGCGATCTAGAG
AGCCCGTTATCTGAAGAGTTCCTGCAAGAAATGGGAAACATCCAAGAGATTTCGCAATCC
ATCGGCGAGGATAGTTCTGGAAGCTTTGGCTTTACGGAATACCAGTATTTAGGAAGCTGT
CCTGGCTCAGATGGCTCGGTCATCACGGACACGCTTTCACCAGCTTCGAGCCCCTCCTCG
GTGACTTATCCTGTGGTCCCCGGCAGCGTGGACGAGTCTCCCAGTGGAGCATTGAACATC
GAATGTAGAATCTGCGGGGACAAGGCCTCAGGCTATCATTACGGAGTCCACGCGTGTGAA
GGCTGCAAGGGCTTCTTTCGGCGAACGATTCGACTCAAGCTGGTGTATGACAAGTGCGAC
CGCAGCTGCAAGATCCAGAAAAAGAACAGAAACAAATGCCAGTATTGTCGATTTCACAAG
TGCCTTTCTGTCGGGATGTCACACAACGCGATTCGTTTTGGACGAATGCCAAGATCTGAG
AAAGCAAAACTGAAAGCAGAAATTCTTACCTGTGAACATGACATAGAAGATTCTGAAACT
GCAGATCTCAAATCTCTGGCCAAGAGAATCTACGAGGCCTACTTGAAGAACTTCAACATG
AACAAGGTCAAAGCCCGGGTCATCCTCTCAGGAAAGGCCAGTAACAATCCACCTTTTGTC
ATACATGATATGGAGACACTGTGTATGGCTGAGAAGACGCTGGTGGCCAAGCTGGTGGCC
AATGGCATCCAGAACAAGGAGGCGGAGGTCCGCATCTTTCACTGCTGCCAGTGCACGTCA
GTGGAGACCGTCACGGAGCTCACGGAATTCGCCAAGGCCATCCCAGGCTTCGCAAACTTG
GACCTGAACGATCAAGTGACATTGCTAAAATACGGAGTTTATGAGGCCATATTCGCCATG
CTGTCTTCTGTGATGAACAAAGACGGGATGCTGGTAGCGTATGGAAATGGGTTTATAACT
CGTGAATTCCTAAAAAGCCTAAGGAAACCGTTCTGTGATATCATGGAACCCAAGTTTGAT
TTTGCCATGAAGTTCAATGCACTGGAACTGGATGACAGTGATATCTCCCTTTTTGTGGCT
GCTATCATTTGCTGTGGAGATCGTCCTGGCCTTCTAAACGTAGGACACATTGAAAAAATG
CAGGAGGGTATTGTACATGTGCTCAGACTCCACCTGCAGAGCAACCACCCGGACGATATC
TTTCTCTTCCCAAAACTTCTTCAAAAAATGGCAGACCTCCGGCAGCTGGTGACGGAGCAT
GCGCAGCTGGTGCAGATCATCAAGAAGACGGAGTCGGATGCTGCGCTGCACCCGCTACTG
CAGGAGATCTACAGGGACATGTACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II repressing transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin conjugating enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>enamel mineralization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of appetite</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cholesterol storage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glycolytic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of leukocyte cell-cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of macrophage derived foam cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of pri-miRNA transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of receptor biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sequestering of triglyceride</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription regulatory region DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fatty acid beta-oxidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fatty acid oxidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gluconeogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cellular ketone metabolic process by positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of glycolytic process by positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of lipid transport by positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to insulin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>wound healing</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0009742</id>
      <name>Matrix metalloproteinase-25</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12345</ref-id>
            <pubmed-id>17353509</pubmed-id>
            <citation>Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, Siwik DA, Liao R, Sam F: Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension. 2007 May;49(5):1084-94. Epub 2007 Mar 12.</citation>
          </article>
          <article>
            <ref-id>A12346</ref-id>
            <pubmed-id>17606858</pubmed-id>
            <citation>Lebrasseur NK, Duhaney TA, De Silva DS, Cui L, Ip PC, Joseph L, Sam F: Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. Hypertension. 2007 Sep;50(3):489-96. Epub 2007 Jul 2.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9NPA2" source="Swiss-Prot">
        <name>Matrix metalloproteinase-25</name>
        <general-function>May activate progelatinase A.</general-function>
        <specific-function>Metalloendopeptidase activity</specific-function>
        <gene-name>MMP25</gene-name>
        <locus>16p13.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-21</signal-regions>
        <theoretical-pi/>
        <molecular-weight>62553.445</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:14246</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1647</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9NPA2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MMP25_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.24.-</synonym>
          <synonym>Leukolysin</synonym>
          <synonym>Membrane-type matrix metalloproteinase 6</synonym>
          <synonym>Membrane-type-6 matrix metalloproteinase</synonym>
          <synonym>MMP-25</synonym>
          <synonym>MMP20</synonym>
          <synonym>MMPL1</synonym>
          <synonym>MT-MMP 6</synonym>
          <synonym>MT6-MMP</synonym>
          <synonym>MT6MMP</synonym>
          <synonym>MTMMP6</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052106|Matrix metalloproteinase-25
MRLRLRLLALLLLLLAPPARAPKPSAQDVSLGVDWLTRYGYLPPPHPAQAQLQSPEKLRD
AIKVMQRFAGLPETGRMDPGTVATMRKPRCSLPDVLGVAGLVRRRRRYALSGSVWKKRTL
TWRVRSFPQSSQLSQETVRVLMSYALMAWGMESGLTFHEVDSPQGQEPDILIDFARAFHQ
DSYPFDGLGGTLAHAFFPGEHPISGDTHFDDEETWTFGSKDGEGTDLFAVAVHEFGHALG
LGHSSAPNSIMRPFYQGPVGDPDKYRLSQDDRDGLQQLYGKAPQTPYDKPTRKPLAPPPQ
PPASPTHSPSFPIPDRCEGNFDAIANIRGETFFFKGPWFWRLQPSGQLVSPRPARLHRFW
EGLPAQVRVVQAAYARHRDGRILLFSGPQFWVFQDRQLEGGARPLTELGLPPGEEVDAVF
SWPQNGKTYLVRGRQYWRYDEAAARPDPGYPRDLSLWEGAPPSPDDVTVSNAGDTYFFKG
AHYWRFPKNSIKTEPDAPQPMGPNWLDCPAPSSGPRAPRPPKATPVSETCDCQCELNQAA
GRWPAPIPLLLLPLLVGGVASR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0052107|Matrix metalloproteinase-25 (MMP25)
ATGCGGCTGCGGCTCCGGCTTCTGGCGCTGCTGCTTCTGCTGCTGGCACCGCCCGCGCGC
GCCCCGAAGCCCTCGGCGCAGGACGTGAGCCTGGGCGTGGACTGGCTGACTCGCTATGGT
TACCTGCCGCCACCCCACCCTGCCCAGGCCCAGCTGCAGAGCCCTGAGAAGTTGCGCGAT
GCCATCAAAGTCATGCAGAGGTTCGCGGGGCTGCCGGAGACCGGCCGCATGGACCCAGGG
ACAGTGGCCACCATGCGTAAGCCCCGCTGCTCCCTGCCTGACGTGCTGGGGGTGGCGGGG
CTGGTCAGGCGGCGTCGCCGGTACGCTCTGAGCGGCAGCGTGTGGAAGAAGCGAACCCTG
ACATGGAGGGTACGTTCCTTCCCCCAGAGCTCCCAGCTGAGCCAGGAGACCGTGCGGGTC
CTCATGAGCTATGCCCTGATGGCCTGGGGCATGGAGTCAGGCCTCACATTTCATGAGGTG
GATTCCCCCCAGGGCCAGGAGCCCGACATCCTCATCGACTTTGCCCGCGCCTTCCACCAG
GACAGCTACCCCTTCGACGGGTTGGGGGGCACCCTAGCCCATGCCTTCTTCCCTGGGGAG
CACCCCATCTCCGGGGACACTCACTTTGACGATGAGGAGACCTGGACTTTTGGGTCAAAA
GACGGCGAGGGGACCGACCTGTTTGCCGTGGCTGTCCATGAGTTTGGCCACGCCCTGGGC
CTGGGCCACTCCTCAGCCCCCAACTCCATTATGAGGCCCTTCTACCAGGGTCCGGTGGGC
GACCCTGACAAGTACCGCCTGTCTCAGGATGACCGCGATGGCCTGCAGCAACTCTATGGG
AAGGCGCCCCAAACCCCATATGACAAGCCCACAAGGAAACCCCTGGCTCCTCCGCCCCAG
CCCCCGGCCTCGCCCACACACAGCCCATCCTTCCCCATCCCTGATCGATGTGAGGGCAAT
TTTGACGCCATCGCCAACATCCGAGGGGAAACTTTCTTCTTCAAAGGCCCCTGGTTCTGG
CGCCTCCAGCCCTCCGGACAGCTGGTGTCCCCGCGACCCGCACGGCTGCACCGCTTCTGG
GAGGGGCTGCCCGCCCAGGTGAGGGTGGTGCAGGCCGCCTATGCTCGGCACCGAGACGGC
CGAATCCTCCTCTTTAGCGGGCCCCAGTTCTGGGTGTTCCAGGACCGGCAGCTGGAGGGC
GGGGCGCGGCCGCTCACGGAGCTGGGGCTGCCCCCGGGAGAGGAGGTGGACGCCGTGTTC
TCGTGGCCACAGAACGGGAAGACCTACCTGGTCCGCGGCCGGCAGTACTGGCGCTACGAC
GAGGCGGCGGCGCGCCCGGACCCCGGCTACCCTCGCGACCTGAGCCTCTGGGAAGGCGCG
CCCCCCTCCCCTGACGATGTCACCGTCAGCAACGCAGGTGACACCTACTTCTTCAAGGGC
GCCCACTACTGGCGCTTCCCCAAGAACAGCATCAAGACCGAGCCGGACGCCCCCCAGCCC
ATGGGGCCCAACTGGCTGGACTGCCCCGCCCCGAGCTCTGGTCCCCGCGCCCCCAGGCCC
CCCAAAGCGACCCCCGTGTCCGAAACCTGCGATTGTCAGTGCGAGCTCAACCAGGCCGCA
GGACGTTGGCCTGCTCCCATCCCGCTGCTCCTCTTGCCCCTGCTGGTGGGGGGTGTAGCC
TCCCGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00045</identifier>
            <name>Hemopexin</name>
          </pfam>
          <pfam>
            <identifier>PF00413</identifier>
            <name>Peptidase_M10</name>
          </pfam>
          <pfam>
            <identifier>PF01471</identifier>
            <name>PG_binding_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>anchored component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>specific granule membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metalloendopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>collagen catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hard palate development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0000956</id>
      <name>Nuclear receptor subfamily 1 group I member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A20117</ref-id>
            <pubmed-id>20024649</pubmed-id>
            <citation>Creusot N, Kinani S, Balaguer P, Tapie N, LeMenach K, Maillot-Marechal E, Porcher JM, Budzinski H, Ait-Aissa S: Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples. Anal Bioanal Chem. 2010 Jan;396(2):569-83. doi: 10.1007/s00216-009-3310-y. Epub 2009 Nov 29.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O75469" source="Swiss-Prot">
        <name>Nuclear receptor subfamily 1 group I member 2</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones. Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes.</specific-function>
        <gene-name>NR1I2</gene-name>
        <locus>3q12-q13.3</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.44</theoretical-pi>
        <molecular-weight>49761.245</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7968</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NR1I2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF061056</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3511138</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>606</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>606</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O75469</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NR1I2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Orphan nuclear receptor PAR1</synonym>
          <synonym>Orphan nuclear receptor PXR</synonym>
          <synonym>Pregnane X receptor</synonym>
          <synonym>PXR</synonym>
          <synonym>Steroid and xenobiotic receptor</synonym>
          <synonym>SXR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001903|Nuclear receptor subfamily 1 group I member 2
MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATGYHFNVMTCEG
CKGFFRRAMKRNARLRCPFRKGACEITRKTRRQCQACRLRKCLESGMKKEMIMSDEAVEE
RRALIKRKKSERTGTQPLGVQGLTEEQRMMIRELMDAQMKTFDTTFSHFKNFRLPGVLSS
GCELPESLQAPSREEAAKWSQVRKDLCSLKVSLQLRGEDGSVWNYKPPADSGGKEIFSLL
PHMADMSTYMFKGIISFAKVISYFRDLPIEDQISLLKGAAFELCQLRFNTVFNAETGTWE
CGRLSYCLEDTAGGFQQLLLEPMLKFHYMLKKLQLHEEEYVLMQAISLFSPDRPGVLQHR
VVDQLQEQFAITLKSYIECNRPQPAHRFLFLKIMAMLTELRSINAQHTQRLLRIQDIHPF
ATPLMQELFGITGS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010672|Nuclear receptor subfamily 1 group I member 2 (NR1I2)
CTGGAGGTGAGACCCAAAGAAAGCTGGAACCATGCTGACTTTGTACACTGTGAGGACACA
GAGTCTGTTCCTGGAAAGCCCAGTGTCAACGCAGATGAGGAAGTCGGAGGTCCCCAAATC
TGCCGTGTATGTGGGGACAAGGCCACTGGCTATCACTTCAATGTCATGACATGTGAAGGA
TGCAAGGGCTTTTTCAGGAGGGCCATGAAACGCAACGCCCGGCTGAGGTGCCCCTTCCGG
AAGGGCGCCTGCGAGATCACCCGGAAGACCCGGCGACAGTGCCAGGCCTGCCGCCTGCGC
AAGTGCCTGGAGAGCGGCATGAAGAAGGAGATGATCATGTCCGACGAGGCCGTGGAGGAG
AGGCGGGCCTTGATCAAGCGGAAGAAAAGTGAACGGACAGGGACTCAGCCACTGGGAGTG
CAGGGGCTGACAGAGGAGCAGCGGATGATGATCAGGGAGCTGATGGACGCTCAGATGAAA
ACCTTTGACACTACCTTCTCCCATTTCAAGAATTTCCGGCTGCCAGGGGTGCTTAGCAGT
GGCTGCGAGTTGCCAGAGTCTCTGCAGGCCCCATCGAGGGAAGAAGCTGCCAAGTGGAGC
CAGGTCCGGAAAGATCTGTGCTCTTTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGC
AGTGTCTGGAACTACAAACCCCCAGCCGACAGTGGCGGGAAAGAGATCTTCTCCCTGCTG
CCCCACATGGCTGACATGTCAACCTACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTC
ATCTCCTACTTCAGGGACTTGCCCATCGAGGACCAGATCTCCCTGCTGAAGGGGGCCGCT
TTCGAGCTGTGTCAACTGAGATTCAACACAGTGTTCAACGCGGAGACTGGAACCTGGGAG
TGTGGCCGGCTGTCCTACTGCTTGGAAGACACTGCAGGTGGCTTCCAGCAACTTCTACTG
GAGCCCATGCTGAAATTCCACTACATGCTGAAGAAGCTGCAGCTGCATGAGGAGGAGTAT
GTGCTGATGCAGGCCATCTCCCTCTTCTCCCCAGACCGCCCAGGTGTGCTGCAGCACCGC
GTGGTGGACCAGCTGCAGGAGCAATTCGCCATTACTCTGAAGTCCTACATTGAATGCAAT
CGGCCCCAGCCTGCTCATAGGTTCTTGTTCCTGAAGATCATGGCTATGCTCACCGAGCTC
CGCAGCATCAATGCTCAGCACACCCAGCGGCTGCTGCGCATCCAGGACATACACCCCTTT
GCTACGCCCCTCATGCAGGAGTTGTTCGGCATCACAGGTAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II regulatory region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug export</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0003538</id>
      <name>UDP-glucuronosyltransferase 1-9</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A34242</ref-id>
            <pubmed-id>15304429</pubmed-id>
            <citation>Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10.</citation>
          </article>
          <article>
            <ref-id>A17495</ref-id>
            <pubmed-id>12582161</pubmed-id>
            <citation>Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, Staels B: The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83. Epub 2003 Feb 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="O60656" source="Swiss-Prot">
        <name>UDP-glucuronosyltransferase 1-9</name>
        <general-function>Retinoic acid binding</general-function>
        <specific-function>UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.</specific-function>
        <gene-name>UGT1A9</gene-name>
        <locus>2q37</locus>
        <cellular-location>Microsome</cellular-location>
        <transmembrane-regions>488-504</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>7.96</theoretical-pi>
        <molecular-weight>59940.495</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12541</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S55985</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>7690346</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O60656</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UD19_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.17</synonym>
          <synonym>GNT1</synonym>
          <synonym>lugP4</synonym>
          <synonym>UDP-glucuronosyltransferase 1-I</synonym>
          <synonym>UDP-glucuronosyltransferase 1A9</synonym>
          <synonym>UDPGT 1-9</synonym>
          <synonym>UGT-1I</synonym>
          <synonym>UGT1</synonym>
          <synonym>UGT1I</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006817|UDP-glucuronosyltransferase 1-9
MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLILRGHEVVVVMP
EVSWQLGRSLNCTVKTYSTSYTLEDLDREFKAFAHAQWKAQVRSIYSLLMGSYNDIFDLF
FSNCRSLFKDKKLVEYLKESSFDAVFLDPFDNCGLIVAKYFSLPSVVFARGILCHYLEEG
AQCPAPLSYVPRILLGFSDAMTFKERVRNHIMHLEEHLLCHRFFKNALEIASEILQTPVT
EYDLYSHTSIWLLRTDFVLDYPKPVMPNMIFIGGINCHQGKPLPMEFEAYINASGEHGIV
VFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGH
PMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDL
ENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTW
YQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012464|UDP-glucuronosyltransferase 1-9 (UGT1A9)
ATGGCTTGCACAGGGTGGACCAGCCCCCTTCCTCTATGTGTGTGTCTGCTGCTGACCTGT
GGCTTTGCCGAGGCAGGGAAGCTACTGGTAGTGCCCATGGATGGGAGCCACTGGTTCACC
ATGAGGTCGGTGGTGGAGAAACTCATTCTCAGGGGGCATGAGGTGGTTGTAGTCATGCCA
GAGGTGAGTTGGCAACTGGGAAGATCACTGAATTGCACAGTGAAGACTTATTCAACTTCA
TATACCCTGGAGGATCTGGACCGGGAGTTCAAGGCTTTTGCCCATGCTCAATGGAAAGCA
CAAGTACGAAGTATATATTCTCTATTAATGGGTTCATACAATGACATTTTTGACTTATTT
TTTTCAAATTGCAGGAGTTTGTTTAAAGACAAAAAATTAGTAGAATACTTAAAGGAGAGT
TCTTTTGATGCAGTGTTTCTCGATCCTTTTGATAACTGTGGCTTAATTGTTGCCAAATAT
TTCTCCCTCCCCTCCGTGGTCTTCGCCAGGGGAATACTTTGCCACTATCTTGAAGAAGGT
GCACAGTGCCCTGCTCCTCTTTCCTATGTCCCCAGAATTCTCTTAGGGTTCTCAGATGCC
ATGACTTTCAAGGAGAGAGTACGGAACCACATCATGCACTTGGAGGAACATTTATTATGC
CACCGTTTTTTCAAAAATGCCCTAGAAATAGCCTCTGAAATTCTCCAAACACCTGTTACG
GAGTATGATCTCTACAGCCACACATCAATTTGGTTGTTGCGAACGGACTTTGTTTTGGAC
TATCCCAAACCCGTGATGCCCAACATGATCTTCATTGGTGGTATCAACTGCCATCAGGGA
AAGCCGTTGCCTATGGAATTTGAAGCCTACATTAATGCTTCTGGAGAACATGGAATTGTG
GTTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCTATGGCAATTGCT
GATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGAACCCGACCATCG
AATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGATCTGCTTGGTCAC
CCGATGACCCGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTATGAAAGCATATGC
AATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGACAATGCAAAGCGC
ATGGAGACTAAGGGAGCTGGAGTGACCCTGAATGTTCTGGAAATGACTTCTGAAGATTTA
GAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAACATCATGCGCCTC
TCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTGTTCTGGGTGGAG
TTTGTGATGAGGCACAAGGGCGCGCCACACCTGCGCCCCGCAGCCCACGACCTCACCTGG
TACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGTCGTGCTGACAGTGGCC
TTCATCACCTTTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGGAAAAAAGGGCGA
GTTAAGAAAGCCCACAAATCCAAGACCCATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00201</identifier>
            <name>UDPGT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="2">
      <id>BE0002705</id>
      <name>Liver carboxylesterase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185972</ref-id>
            <pubmed-id>23386599</pubmed-id>
            <citation>Laizure SC, Herring V, Hu Z, Witbrodt K, Parker RB: The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy. 2013 Feb;33(2):210-22. doi: 10.1002/phar.1194.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P23141" source="Swiss-Prot">
        <name>Liver carboxylesterase 1</name>
        <general-function>Triglyceride lipase activity</general-function>
        <specific-function>Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity, catalyzing the ethyl esterification of oleic acid to ethyloleate.</specific-function>
        <gene-name>CES1</gene-name>
        <locus>16q13-q22.1</locus>
        <cellular-location>Endoplasmic reticulum lumen</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-17</signal-regions>
        <theoretical-pi>6.58</theoretical-pi>
        <molecular-weight>62520.62</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1863</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CES1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M73499</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2592</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P23141</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>EST1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ACAT</synonym>
          <synonym>Acyl-coenzyme A:cholesterol acyltransferase</synonym>
          <synonym>Brain carboxylesterase hBr1</synonym>
          <synonym>Carboxylesterase 1</synonym>
          <synonym>CE-1</synonym>
          <synonym>CES2</synonym>
          <synonym>Cocaine carboxylesterase</synonym>
          <synonym>Egasyn</synonym>
          <synonym>hCE-1</synonym>
          <synonym>HMSE</synonym>
          <synonym>Methylumbelliferyl-acetate deacetylase 1</synonym>
          <synonym>Monocyte/macrophage serine esterase</synonym>
          <synonym>REH</synonym>
          <synonym>Retinyl ester hydrolase</synonym>
          <synonym>Serine esterase 1</synonym>
          <synonym>SES1</synonym>
          <synonym>TGH</synonym>
          <synonym>Triacylglycerol hydrolase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005305|Liver carboxylesterase 1
MWLRAFILATLSASAAWGHPSSPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPPL
GPLRFTPPQPAEPWSFVKNATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYLN
IYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFST
GDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGESAGGESVSVLVLSPLAKNLF
HRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTLK
MKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLIP
MQLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLDL
IADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAPF
LKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKLK
DKEVAFWTNLFAKKAVEKPPQTEHIEL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021334|Liver carboxylesterase 1 (CES1)
ATGTGGCTCCGTGCCTTTATCCTGGCCACTCTCTCTGCTTCCGCGGCTTGGGGGCATCCG
TCCTCGCCACCTGTGGTGGACACCGTGCATGGCAAAGTGCTGGGGAAGTTCGTCAGCTTA
GAAGGATTTGCACAGCCTGTGGCCATTTTCCTGGGAATCCCTTTTGCCAAGCCGCCTCTT
GGACCCCTGAGGTTTACTCCACCGCAGCCTGCAGAACCATGGAGCTTTGTGAAGAATGCC
ACCTCGTACCCTCCTATGTGCACCCAAGATCCCAAGGCGGGGCAGTTACTCTCAGAGCTA
TTTACAAACCGAAAGGAGAACATTCCTCTCAAGCTTTCTGAAGACTGTCTTTACCTCAAT
ATTTACACTCCTGCTGACTTGACCAAGAAAAACAGGCTGCCGGTGATGGTGTGGATCCAC
GGAGGGGGGCTGATGGTGGGTGCGGCATCAACCTATGATGGGCTGGCCCTTGCTGCCCAT
GAAAACGTGGTGGTGGTGACCATTCAATATCGCCTGGGCATCTGGGGATTCTTCAGCACA
GGGGATGAACACAGCCGGGGGAACTGGGGTCACCTGGACCAGGTGGCTGCCCTGCGCTGG
GTCCAGGACAACATTGCCAGCTTTGGAGGGAACCCAGGCTCTGTGACCATCTTTGGAGAG
TCAGCGGGAGGAGAAAGTGTCTCTGTTCTTGTTTTGTCTCCATTGGCCAAGAACCTCTTC
CACCGGGCCATTTCTGAGAGTGGCGTGGCCCTCACTTCTGTTCTGGTGAAGAAAGGTGAT
GTCAAGCCCTTGGCTGAGCAAATTGCTATCACTGCTGGGTGCAAAACCACCACCTCTGCT
GTCATGGTTCACTGCCTGCGACAGAAGACGGAAGAGGAGCTCTTGGAGACGACATTGAAA
ATGAAATTCTTATCTCTGGACTTACAGGGAGACCCCAGAGAGAGTCAACCCCTTCTGGGC
ACTGTGATTGATGGGATGCTGCTGCTGAAAACACCTGAAGAGCTTCAAGCTGAAAGGAAT
TTCCACACTGTCCCCTACATGGTCGGAATTAACAAGCAGGAGTTTGGCTGGTTGATTCCA
ATGCAGTTGATGAGCTATCCACTCTCCGAAGGGCAACTGGACCAGAAGACAGCCATGTCA
CTCCTGTGGAAGTCCTATCCCCTTGTTTGCATTGCTAAGGAACTGATTCCAGAAGCCACT
GAGAAATACTTAGGAGGAACAGACGACACTGTCAAAAAGAAAGACCTGTTCCTGGACTTG
ATAGCAGATGTGATGTTTGGTGTCCCATCTGTGATTGTGGCCCGGAACCACAGAGATGCT
GGAGCACCCACCTACATGTATGAGTTTCAGTACCGTCCAAGCTTCTCATCAGACATGAAA
CCCAAGACGGTGATAGGAGACCACGGGGATGAGCTCTTCTCCGTCTTTGGGGCCCCATTT
TTAAAAGAGGGTGCCTCAGAAGAGGAGATCAGACTTAGCAAGATGGTGATGAAATTCTGG
GCCAACTTTGCTCGCAATGGAAACCCCAATGGGGAAGGGCTGCCCCACTGGCCAGAGTAC
AACCAGAAGGAAGGGTATCTGCAGATTGGTGCCAACACCCAGGCGGCCCAGAAGCTGAAG
GACAAAGAAGTAGCTTTCTGGACCAACCTCTTTGCCAAGAAGGCAGTGGAGAAGCCACCC
CAGACAGAACACATAGAGCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00135</identifier>
            <name>COesterase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carboxylic ester hydrolase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>methylumbelliferyl-acetate deacetylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sterol esterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>triglyceride lipase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="3">
      <id>BE0003074</id>
      <name>Carbonyl reductase [NADPH] 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185984</ref-id>
            <pubmed-id>27599626</pubmed-id>
            <citation>Malatkova P, Kanavi M, Nobilis M, Wsol V: In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. doi: 10.1016/j.cbi.2016.09.001. Epub 2016 Sep 4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16152" source="Swiss-Prot">
        <name>Carbonyl reductase [NADPH] 1</name>
        <general-function>Prostaglandin-e2 9-reductase activity</general-function>
        <specific-function>NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.</specific-function>
        <gene-name>CBR1</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.49</theoretical-pi>
        <molecular-weight>30374.73</molecular-weight>
        <chromosome-location>21</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1548</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CBR1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J04056</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1383</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16152</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CBR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.1.1.184</synonym>
          <synonym>15-hydroxyprostaglandin dehydrogenase [NADP(+)]</synonym>
          <synonym>CBR</synonym>
          <synonym>CRN</synonym>
          <synonym>NADPH-dependent carbonyl reductase 1</synonym>
          <synonym>Prostaglandin 9-ketoreductase</synonym>
          <synonym>Prostaglandin-E(2) 9-reductase</synonym>
          <synonym>SDR21C1</synonym>
          <synonym>Short chain dehydrogenase/reductase family 21C member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006005|Carbonyl reductase [NADPH] 1
MSSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFH
QLDIDDLQSIRALRDFLRKEYGGLDVLVNNAGIAFKVADPTPFHIQAEVTMKTNFFGTRD
VCTELLPLIKPQGRVVNVSSIMSVRALKSCSPELQQKFRSETITEEELVGLMNKFVEDTK
KGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKA
TKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012150|Carbonyl reductase [NADPH] 1 (CBR1)
ATGTCGTCCGGCATCCATGTAGCGCTGGTGACTGGAGGCAACAAGGGCATCGGCTTGGCC
ATCGTGCGCGACCTGTGCCGGCTGTTCTCGGGGGACGTGGTGCTCACGGCGCGGGACGTG
ACGCGGGGCCAGGCGGCCGTACAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCAC
CAGCTGGACATCGACGATCTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAG
TACGGGGGCCTGGACGTGCTGGTCAACAACGCGGGCATCGCCTTCAAGGTTGCTGATCCC
ACACCCTTTCATATTCAAGCTGAAGTGACGATGAAAACAAATTTCTTTGGTACCCGAGAT
GTGTGCACAGAATTACTCCCTCTAATAAAACCCCAAGCATCCTGCGTACTGTCTGCATGG
TCATGCCTCTCCCAAAATCCTTCAGGAGGAAAGTCCAAGCCCTTAGCATGGTTCACAGAG
ATGTCCATAATCTGCCGCTGCTTAACTCTGGGCCCATTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00106</identifier>
            <name>adh_short</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>15-hydroxyprostaglandin dehydrogenase (NADP+) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carbonyl reductase (NADPH) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin-E2 9-reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cyclooxygenase pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin K metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="4">
      <id>BE0002887</id>
      <name>Cytochrome P450 2C8</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15162</ref-id>
            <pubmed-id>15601807</pubmed-id>
            <citation>Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.</citation>
          </article>
          <article>
            <ref-id>A38112</ref-id>
            <pubmed-id>26721703</pubmed-id>
            <citation>Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411.</citation>
          </article>
          <article>
            <ref-id>A184160</ref-id>
            <pubmed-id>27720395</pubmed-id>
            <citation>Gong Y, Shao Z, Fu Z, Edin ML, Sun Y, Liegl RG, Wang Z, Liu CH, Burnim SB, Meng SS, Lih FB, SanGiovanni JP, Zeldin DC, Hellstrom A, Smith LEH: Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Nov;13:201-211. doi: 10.1016/j.ebiom.2016.09.025. Epub 2016 Sep 30.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L8588</ref-id>
            <title>FDA Approved Drug Products: Fenofibrate Oral Tablets</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf</url>
          </link>
          <link>
            <ref-id>L8591</ref-id>
            <title>FDA Approved Drug Products: Fenofibrate Oral Capsules</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10632" source="Swiss-Prot">
        <name>Cytochrome P450 2C8</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).</specific-function>
        <gene-name>CYP2C8</gene-name>
        <locus>10q23.33</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.62</theoretical-pi>
        <molecular-weight>55824.275</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2622</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M17397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1325</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10632</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIC8</synonym>
          <synonym>Cytochrome P450 form 1</synonym>
          <synonym>Cytochrome P450 IIC2</synonym>
          <synonym>Cytochrome P450 MP-12</synonym>
          <synonym>Cytochrome P450 MP-20</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005650|Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021338|Cytochrome P450 2C8 (CYP2C8)
ATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG
AGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA
AATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC
TATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT
GAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC
CCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCACAACCTTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
GTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA
TTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT
CTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA
CGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT
CGGGACTTTATCGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA
GAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG
ACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG
GATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC
CTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC
ATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA
TTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG
AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT
GCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT
GTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA
CCCTCATACCAGATCTGCTTCATCCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="4">
      <id>BE0003536</id>
      <name>Cytochrome P450 2C19</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L8588</ref-id>
            <title>FDA Approved Drug Products: Fenofibrate Oral Tablets</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf</url>
          </link>
          <link>
            <ref-id>L8591</ref-id>
            <title>FDA Approved Drug Products: Fenofibrate Oral Capsules</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P33261" source="Swiss-Prot">
        <name>Cytochrome P450 2C19</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.</specific-function>
        <gene-name>CYP2C19</gene-name>
        <locus>10q24.1-q24.3</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.42</theoretical-pi>
        <molecular-weight>55930.545</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2621</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M61854</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1328</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P33261</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2CJ_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(R)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 7-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>CYPIIC17</synonym>
          <synonym>CYPIIC19</synonym>
          <synonym>Cytochrome P450-11A</synonym>
          <synonym>Cytochrome P450-254C</synonym>
          <synonym>Mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020694|Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020695|Cytochrome P450 2C19 (CYP2C19)
ATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT
GAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA
TTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC
ACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG
GAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT
CGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT
GAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG
ACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG
GACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC
CTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC
ATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG
AAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG
GCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT
CTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG
CCCTTCTATCAGCTGTGCTTCATTCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(R)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 7-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="5">
      <id>BE0003336</id>
      <name>Cytochrome P450 2A6</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L8588</ref-id>
            <title>FDA Approved Drug Products: Fenofibrate Oral Tablets</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf</url>
          </link>
          <link>
            <ref-id>L8591</ref-id>
            <title>FDA Approved Drug Products: Fenofibrate Oral Capsules</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11509" source="Swiss-Prot">
        <name>Cytochrome P450 2A6</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.</specific-function>
        <gene-name>CYP2A6</gene-name>
        <locus>19q13.2</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.69</theoretical-pi>
        <molecular-weight>56501.005</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2610</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2A6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X13897</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1321</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11509</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2A6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,4-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Coumarin 7-hydroxylase</synonym>
          <synonym>CYP2A3</synonym>
          <synonym>CYPIIA6</synonym>
          <synonym>Cytochrome P450 IIA3</synonym>
          <synonym>Cytochrome P450(I)</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037226|Cytochrome P450 2A6
MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMK
ISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSN
GERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDALRGTGGANIDPTFFLSRTVSN
VISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQL
LQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFI
GGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQ
RFGDVIPMSLARRVKKDTKFRDFFLPKGTEVFPMLGSVLRDPSFFSNPQDFNPQHFLNEK
GQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGF
ATIPRNYTMSFLPR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021356|Cytochrome P450 2A6 (CYP2A6)
ATGCTGGCCTCAGGGATGCTTCTGGTGGCCTTGCTGGTCTGCCTGACTGTAATGGTCTTG
ATGTCTGTTTGGCAGCAGAGGAAGAGCAAGGGGAAGCTGCCTCCGGGACCCACCCCATTG
CCCTTCATTGGAAACTACCTGCAGCTGAACACAGAGCAGATGTACAACTCCCTCATGAAG
ATCAGTGAGCGCTATGGCCCCGTGTTCACCATTCACTTGGGGCCCCGGCGGGTCGTGGTG
CTGTGTGGACATGATGCCGTCAGGGAGGCTCTGGTGGACCAGGCTGAGGAGTTCAGCGGG
CGAGGCGAGCAAGCCACCTTCGACTGGGTCTTCAAAGGCTATGGCGTGGTATTCAGCAAC
GGGGAGCGCGCCAAGCAGCTCCGGCGCTTCTCCATCGCCACCCTGCGGGACTTCGGGGTG
GGCAAGCGAGGCATCGAGGAGCGCATCCAGGAGGAGGCGGGCTTCCTCATCGACGCCCTC
CGGGGCACTGGCGGCGCCAATATCGATCCCACCTTCTTCCTGAGCCGCACAGTCTCCAAT
GTCATCAGCTCCATTGTCTTTGGGGACCGCTTTGACTATAAGGACAAAGAGTTCCTGTCA
CTGTTGCGCATGATGCTAGGAATCTTCCAGTTCACGTCAACCTCCACGGGGCAGCTCTAT
GAGATGTTCTCTTCGGTGATGAAACACCTGCCAGGACCACAGCAACAGGCCTTTCAGTTG
CTGCAAGGGCTGGAGGACTTCATAGCCAAGAAGGTGGAGCACAACCAGCGCACGCTGGAT
CCCAATTCCCCACGGGACTTCATTGACTCCTTTCTCATCCGCATGCAGGAGGAGGAGAAG
AACCCCAACACGGAGTTCTACTTGAAAAACCTGGTGATGACCACGTTGAACCTCTTCATT
GGGGGCACCGAGACCGTCAGCACCACCCTGCGCTATGGCTTCTTGCTGCTCATGAAGCAC
CCAGAGGTGGAGGCCAAGGTCCATGAGGAGATTGACAGAGTGATCGGCAAGAACCGGCAG
CCCAAGTTTGAGGACCGGGCCAAGATGCCCTACATGGAGGCAGTGATCCACGAGATCCAA
AGATTTGGAGACGTGATCCCCATGAGTTTGGCCCGCAGAGTCAAAAAGGACACCAAGTTT
CGGGATTTCTTCCTCCCTAAGGGCACCGAAGTGTACCCTATGCTGGGCTCTGTGCTGAGA
GACCCCAGTTTCTTCTCCAACCCCCAGGACTTCAATCCCCAGCACTTCCTGAATGAGAAG
GGGCAGTTTAAGAAGAGTGATGCTTTTGTGCCCTTTTCCATCGGAAAGCGGAACTGTTTC
GGAGAAGGCCTGGCCAGAATGGAGCTCTTTCTCTTCTTCACCACCGTCATGCAGAACTTC
CGCCTCAAGTCCTCCCAGTCACCTAAGGACATTGACGTGTCCCCCAAACACGTGGGCTTT
GCCACGATCCCACGAAACTACACCATGAGCTTCCTGCCCCGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic microtubule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>coumarin 7-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="6">
      <id>BE0000126</id>
      <name>Aldo-keto reductase family 1 member C1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185984</ref-id>
            <pubmed-id>27599626</pubmed-id>
            <citation>Malatkova P, Kanavi M, Nobilis M, Wsol V: In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. doi: 10.1016/j.cbi.2016.09.001. Epub 2016 Sep 4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q04828" source="Swiss-Prot">
        <name>Aldo-keto reductase family 1 member C1</name>
        <general-function>Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity</general-function>
        <specific-function>Converts progesterone to its inactive form, 20-alpha-dihydroxyprogesterone (20-alpha-OHP). In the liver and intestine, may have a role in the transport of bile. May have a role in monitoring the intrahepatic bile acid concentration. Has a low bile-binding ability. May play a role in myelin formation.</specific-function>
        <gene-name>AKR1C1</gene-name>
        <locus>10p15-p14</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.99</theoretical-pi>
        <molecular-weight>36788.02</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:384</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>AKR1C1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M86609</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181549</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q04828</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>AK1C1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.1.1.-</synonym>
          <synonym>20-alpha-HSD</synonym>
          <synonym>20-alpha-hydroxysteroid dehydrogenase</synonym>
          <synonym>Chlordecone reductase homolog HAKRC</synonym>
          <synonym>DD1/DD2</synonym>
          <synonym>DDH</synonym>
          <synonym>DDH1</synonym>
          <synonym>Dihydrodiol dehydrogenase 1/2</synonym>
          <synonym>HBAB</synonym>
          <synonym>High-affinity hepatic bile acid-binding protein</synonym>
          <synonym>Indanol dehydrogenase</synonym>
          <synonym>Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016017|Aldo-keto reductase family 1 member C1
MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPV
SVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKP
GLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLN
RNVRYLTLDIFAGPPNYPFSDEY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016018|Aldo-keto reductase family 1 member C1 (AKR1C1)
ATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGA
TTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTG
GCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA
AGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTG
TCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGAC
ACAGTGGATCTCTGTGCCACATGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCC
AAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCA
GGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGA
AAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGA
TCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTC
CTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG
CTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC
GTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAAC
AGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCT
GATGAATATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00248</identifier>
            <name>Aldo_ket_red</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alditol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aldo-keto reductase (NADP) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>androsterone dehydrogenase (B-specific) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carboxylic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>indanol dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ketosteroid monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phenanthrene 9,10-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to jasmonic acid stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>daunorubicin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>doxorubicin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestinal cholesterol absorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phototransduction, visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>progesterone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organophosphorus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinal metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="7">
      <id>BE0000622</id>
      <name>Aldo-keto reductase family 1 member C2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185984</ref-id>
            <pubmed-id>27599626</pubmed-id>
            <citation>Malatkova P, Kanavi M, Nobilis M, Wsol V: In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. doi: 10.1016/j.cbi.2016.09.001. Epub 2016 Sep 4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P52895" source="Swiss-Prot">
        <name>Aldo-keto reductase family 1 member C2</name>
        <general-function>Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity</general-function>
        <specific-function>Works in concert with the 5-alpha/5-beta-steroid reductases to convert steroid hormones into the 3-alpha/5-alpha and 3-alpha/5-beta-tetrahydrosteroids. Catalyzes the inactivation of the most potent androgen 5-alpha-dihydrotestosterone (5-alpha-DHT) to 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-diol). Has a high bile-binding ability.</specific-function>
        <gene-name>AKR1C2</gene-name>
        <locus>10p15-p14</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.55</theoretical-pi>
        <molecular-weight>36734.97</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:385</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>AKR1C2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U05598</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>531160</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P52895</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>AK1C2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.-.-.-</synonym>
          <synonym>3-alpha-HSD3</synonym>
          <synonym>Chlordecone reductase homolog HAKRD</synonym>
          <synonym>DD-2</synonym>
          <synonym>DD/BABP</synonym>
          <synonym>DD2</synonym>
          <synonym>DDH2</synonym>
          <synonym>Dihydrodiol dehydrogenase 2</synonym>
          <synonym>Dihydrodiol dehydrogenase/bile acid-binding protein</synonym>
          <synonym>Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase</synonym>
          <synonym>Type III 3-alpha-hydroxysteroid dehydrogenase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001240|Aldo-keto reductase family 1 member C2
MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHIDSAHVYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLDYVDLYLIHFPV
SVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNHRLLEMILNKP
GLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLN
RNVRYLTLDIFAGPPNYPFSDEY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010433|Aldo-keto reductase family 1 member C2 (AKR1C2)
ATGGATTCGAAATACCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGA
TTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTCTAGAGGCCGTCAAATTG
GCAATAGAAGCCGGGTTCCACCATATTGATTCTGCACATGTTTACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGAGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA
AGGTCACTGAAAAATCTTCAATTGGACTATGTTGACCTCTATCTTATTCATTTTCCAGTG
TCTGTAAAGGAGGACATAGGGATTTTAACATGGAAGAAGAGCCCTAAACATAACTCCTAA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00248</identifier>
            <name>Aldo_ket_red</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alditol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carboxylic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ketosteroid monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phenanthrene 9,10-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to jasmonic acid stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to prostaglandin D stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>daunorubicin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>doxorubicin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>progesterone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="8">
      <id>BE0000592</id>
      <name>Aldo-keto reductase family 1 member C3</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185984</ref-id>
            <pubmed-id>27599626</pubmed-id>
            <citation>Malatkova P, Kanavi M, Nobilis M, Wsol V: In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. doi: 10.1016/j.cbi.2016.09.001. Epub 2016 Sep 4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P42330" source="Swiss-Prot">
        <name>Aldo-keto reductase family 1 member C3</name>
        <general-function>Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity</general-function>
        <specific-function>Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.</specific-function>
        <gene-name>AKR1C3</gene-name>
        <locus>10p15-p14</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.06</theoretical-pi>
        <molecular-weight>36852.89</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:386</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>AKR1C3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S68288</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4261711</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1382</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P42330</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>AK1C3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.-.-.-</synonym>
          <synonym>17-beta-HSD 5</synonym>
          <synonym>17-beta-hydroxysteroid dehydrogenase type 5</synonym>
          <synonym>3-alpha-HSD type 2</synonym>
          <synonym>3-alpha-HSD type II, brain</synonym>
          <synonym>3-alpha-hydroxysteroid dehydrogenase type 2</synonym>
          <synonym>Chlordecone reductase homolog HAKRb</synonym>
          <synonym>DD-3</synonym>
          <synonym>DD3</synonym>
          <synonym>DDH1</synonym>
          <synonym>Dihydrodiol dehydrogenase 3</synonym>
          <synonym>Dihydrodiol dehydrogenase type I</synonym>
          <synonym>HA1753</synonym>
          <synonym>HSD17B5</synonym>
          <synonym>Indanol dehydrogenase</synonym>
          <synonym>KIAA0119</synonym>
          <synonym>PGFS</synonym>
          <synonym>Prostaglandin F synthase</synonym>
          <synonym>Testosterone 17-beta-dehydrogenase 5</synonym>
          <synonym>Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037052|Aldo-keto reductase family 1 member C3
MDSKHQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPM
SLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKP
GLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLD
RNLHYFNSDSFASHPNYPYSDEY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018982|Aldo-keto reductase family 1 member C3 (AKR1C3)
ATGGATTCAAAACATCAGTGTTTGAAGCTAAATGATGGTCACTTCATGCCTGTCCTGGGA
TTTGGCACCTATGCACCTCCAGAGGTTCCGAGAAGTAAAGCTTTGGAGGTCACAAAATTA
GCAATAGAAGCTGGGTTCCGCCATATAGATTCTGCTCATTTATACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGTCCACTTTTCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA
AACTCACTGAAGAAAGCTCAATTGGACTATGTTGACCTCTATCTTATTCATTCTCCAATG
TCTCTAAAGCCAGGTGAGGAACTTTCACCAACAGATGAAAATGGAAAAGTAATATTTGAC
ATAGTGGATCTCTGTACCACCTGGGAGGCCATGGAGAAGTGTAAGGATGCAGGATTGGCC
AAGTCCATTGGGGTGTCAAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCA
GGACTCAAGTACAAGCCTGTCTGCAACCAGGTAGAATGTCATCCGTATTTCAACCGGAGT
AAATTGCTAGATTTCTGCAAGTCGAAAGATATTGTTCTGGTTGCCTATAGTGCTCTGGGA
TCTCAACGAGACAAACGATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTC
CTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG
CTGCAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC
GTGCAGGTTTTTGAGTTCCAGTTGACTGCAGAGGACATGAAAGCCATAGATGGCCTAGAC
AGAAATCTCCACTATTTTAACAGTGATAGTTTTGCTAGCCACCCTAATTATCCATATTCA
GATGAATATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00248</identifier>
            <name>Aldo_ket_red</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alditol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aldo-keto reductase (NADP) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>androsterone dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>delta4-3-oxosteroid 5beta-reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dihydrotestosterone 17-beta-dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>geranylgeranyl reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>indanol dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ketoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ketosteroid monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phenanthrene 9,10-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin D2 11-ketoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin-F synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinal dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinol dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 17-beta-dehydrogenase (NADP+) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone dehydrogenase (NAD+) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to calcium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to corticosteroid stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to jasmonic acid stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to prostaglandin D stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to prostaglandin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to reactive oxygen species</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cyclooxygenase pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>daunorubicin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>doxorubicin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>farnesol catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>keratinocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organismal macromolecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of retinoic acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phototransduction, visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of endothelial cell apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of reactive oxygen species metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>progesterone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein import into nucleus, translocation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of retinoic acid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of testosterone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal absorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinal metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>testosterone biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="9">
      <id>BE0000747</id>
      <name>Aldose reductase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185984</ref-id>
            <pubmed-id>27599626</pubmed-id>
            <citation>Malatkova P, Kanavi M, Nobilis M, Wsol V: In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. doi: 10.1016/j.cbi.2016.09.001. Epub 2016 Sep 4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P15121" source="Swiss-Prot">
        <name>Aldose reductase</name>
        <general-function>Glyceraldehyde oxidoreductase activity</general-function>
        <specific-function>Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.</specific-function>
        <gene-name>AKR1B1</gene-name>
        <locus>7q35</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.99</theoretical-pi>
        <molecular-weight>35853.125</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:381</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>AKR1B1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J04795</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178487</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P15121</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ALDR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.1.1.21</synonym>
          <synonym>Aldehyde reductase</synonym>
          <synonym>Aldo-keto reductase family 1 member B1</synonym>
          <synonym>ALDR1</synonym>
          <synonym>AR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016194|Aldose reductase
MASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQ
EKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGK
EFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKP
AVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAK
HNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCA
LLSCTSHKDYPFHEEF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016195|Aldose reductase (AKR1B1)
ATGGCAAGCCGTCTCCTGCTCAACAACGGCGCCAAGATGCCCATCCTGGGGTTGGGTACC
TGGAAGTCCCCTCCAGGGCAGGTGACTGAGGCCGTGAAGGTGGCCATTGACGTCGGGTAC
CGCCACATCGACTGTGCCCATGTGTACCAGAATGAGAATGAGGTGGGGGTGGCCATTCAG
GAGAAGCTCAGGGAGCAGGTGGTGAAGCGTGAGGAGCTCTTCATCGTCAGCAAGCTGTGG
TGCACGTACCATGAGAAGGGCCTGGTGAAAGGAGCCTGCCAGAAGACACTCAGCGACCTG
AAGCTGGACTACCTGGACCTCTACCTTATTCACTGGCCGACTGGCTTTAAGCCTGGGAAG
GAATTTTTCCCATTGGATGAGTCGGGCAATGTGGTTCCCAGTGACACCAACATTCTGGAC
ACGTGGGCGGCCATGGAAGAGCTGGTGGATGAAGGGCTGGTGAAAGCTATTGGCATCTCC
AACTTCAACCATCTCCAGGTGGAGATGATCTTAAACAAACCTGGCTTGAAGTATAAGCCT
GCAGTTAACCAGATTGAGTGCCACCCATATCTCACTCAGGAGAAGTTAATCCAGTACTGC
CAGTCCAAAGGCATCGTGGTGACCGCCTACAGCCCCCTCGGCTCTCCTGACAGGCCCTGG
GCCAAGCCCGAGGACCCTTCTCTCCTGGAGGATCCCAGGATCAAGGCGATCGCAGCCAAG
CACAATAAAACTACAGCCCAGGTCCTGATCCGGTTCCCCATGCAGAGGAACTTGGTGGTG
ATCCCCAAGTCTGTGACACCAGAACGCATTGCTGAGAACTTTAAGGTCTTTGACTTTGAA
CTGAGCAGCCAGGATATGACCACCTTACTCAGCTACAACAGGAACTGGAGGGTCTGTGCC
TTGTTGAGCTGTACCTCCCACAAGGATTACCCCTTCCATGAAGAGTTTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00248</identifier>
            <name>Aldo_ket_red</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell projection cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mast cell granule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>paranodal junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Schmidt-Lanterman incisure</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Schwann cell microvillus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alditol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aldo-keto reductase (NADP) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glyceraldehyde oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>C21-steroid hormone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carbohydrate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hydrogen peroxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to methylglyoxal</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to peptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>daunorubicin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>doxorubicin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fructose biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fructose metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inner medullary collecting duct development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maternal process involved in female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>naphthalene metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>norepinephrine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of JAK-STAT cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to thyroid hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to water deprivation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sorbitol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stress-activated protein kinase signaling cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tissue homeostasis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="10">
      <id>BE0002793</id>
      <name>Cytochrome P450 2C9</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A39443</ref-id>
            <pubmed-id>27026863</pubmed-id>
            <citation>Prasad GS, Srisailam K, Sashidhar RB: Metabolic inhibition of meloxicam by specific CYP2C9 inhibitors in Cunninghamella blakesleeana NCIM 687: in silico and in vitro studies. Springerplus. 2016 Feb 24;5:166. doi: 10.1186/s40064-016-1794-4. eCollection 2016.</citation>
          </article>
          <article>
            <ref-id>A36413</ref-id>
            <pubmed-id>12549950</pubmed-id>
            <citation>Kim KY, Mancano MA: Fenofibrate potentiates warfarin effects. Ann Pharmacother. 2003 Feb;37(2):212-5. doi: 10.1177/106002800303700210.</citation>
          </article>
          <article>
            <ref-id>A39444</ref-id>
            <pubmed-id>14682608</pubmed-id>
            <citation>Fujino H, Yamada I, Shimada S, Hirano M, Tsunenari Y, Kojima J: Interaction between fibrates and statins--metabolic interactions with gemfibrozil. Drug Metabol Drug Interact. 2003;19(3):161-76.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11712" source="Swiss-Prot">
        <name>Cytochrome P450 2C9</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.</specific-function>
        <gene-name>CYP2C9</gene-name>
        <locus>10q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.99</theoretical-pi>
        <molecular-weight>55627.365</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2623</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AY341248</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1326</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11712</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C9_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(R)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 7-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP2C10</synonym>
          <synonym>CYPIIC9</synonym>
          <synonym>Cytochrome P-450MP</synonym>
          <synonym>Cytochrome P450 MP-4</synonym>
          <synonym>Cytochrome P450 MP-8</synonym>
          <synonym>Cytochrome P450 PB-1</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005471|Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016893|Cytochrome P450 2C9 (CYP2C9)
ATGGATTCTCTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGAAACCCATAGTGGTGCTGCATGGATAT
GAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATTGTTTTCAGCAATGGAAAGAAATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCATAAACGTTTTGATTATAAAGATCAGCAATTTCTTAACTTAATGGAAAAG
TTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCT
CCTATCATTGATTACTTCCCGGGAACTCACAACAAATTACTTAAAAACGTTGCTTTTATG
AAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCT
CAGGACTTTATTGATTGCTTCCTGATGAAAATGGAGAAGGAAAAGCACAACCAACCATCT
GAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAG
ACGACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAA
GACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATTGAC
CTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTC
ATTCCCAAGGGCACAACCATATTAATTTCCCTGACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAG
AAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAAGCCCTG
GCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCT
CTGGTTGACCCAAAGAACCTTGACACCACTCCAGTTGTCAATGGATTTGCCTCTGTGCCG
CCCTTCTACCAGCTGTGCTTCATTCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(R)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 7-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular amide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urea metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers>
    <carrier position="12">
      <id>BE0000530</id>
      <name>Serum albumin</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185936</ref-id>
            <pubmed-id>3318449</pubmed-id>
            <citation>Chapman MJ: Pharmacology of fenofibrate. Am J Med. 1987 Nov 27;83(5B):21-5. doi: 10.1016/0002-9343(87)90867-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02768" source="Swiss-Prot">
        <name>Serum albumin</name>
        <general-function>Toxic substance binding</general-function>
        <specific-function>Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.</specific-function>
        <gene-name>ALB</gene-name>
        <locus>4q11-q13</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.21</theoretical-pi>
        <molecular-weight>69365.94</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>V00494</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ALBU_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Serum albumin precursor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001058|Serum albumin
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010372|Serum albumin (ALB)
ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGT
GTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAA
GAAAATTTCAAAGCCTTGGTGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTT
GAAGATCATGTAAAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGAT
GAGTCAGCTGAAAATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACA
GTTGCAACTCTTCGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCT
GAGAGAAATGAATGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCCGATTGGTG
AGACCAGAGGTTGATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTTGAAA
AAATACTTATATGAAATTGCCAGAAGACATCCTTACTTTTATGCCCCGGAACTCCTTTTC
TTTGCTAAAAGGTATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCC
TGCCTGTTGCCAAAGCTCGATGAACTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAG
AGACTCAAGTGTGCCAGTCTCCAAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTA
GCTCGCCTGAGCCAGAGATTTCCCAAAGCTGAGTTTGCAGAAGTTTCCAAGTTAGTGACA
GATCTTACCAAAGTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGAC
AGGGCGGACCTTGCCAAGTATATCTGTGAAAATCAAGATTCGATCTCCAGTAAACTGAAG
GAATGCTGTGAAAAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGAT
GAGATGCCTGCTGACTTGCCTTCATTAGCTGCTGATTTTGTTGAAAGTAAGGATGTTTGC
AAAAACTATGCTGAGGCAAAGGATGTCTTCCTGGGCATGTTTTTGTATGAATATGCAAGA
AGGCATCCTGATTACTCTGTCGTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACT
CTAGAGAAGTGCTGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTCGATGAA
TTTAAACCTCTTGTGGAAGAGCCTCAGAATTTAATCAAACAAAATTGTGAGCTTTTTGAG
CAGCTTGGAGAGTACAAATTCCAGAATGCGCTATTAGTTCGTTACACCAAGAAAGTACCC
CAAGTGTCAACTCCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAA
TGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTGGTC
CTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAATGC
TGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACA
TACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACACTT
TCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTCGTGAAACACAAG
CCCAAGGCAACAAAAGAGCAACTGAAAGCTGTTATGGATGATTTCGCAGCTTTTGTAGAG
AAGTGCTGCAAGGCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTT
GCTGCAAGTCAAGCTGCCTTAGGCTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00273</identifier>
            <name>Serum_albumin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antioxidant activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chaperone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>copper ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>toxic substance binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hemolysis by symbiont of host erythrocytes</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of mitochondrion location</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters>
    <transporter position="11">
      <id>BE0000703</id>
      <name>Bile salt export pump</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A33345</ref-id>
            <pubmed-id>24014644</pubmed-id>
            <citation>Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="O95342" source="Swiss-Prot">
        <name>Bile salt export pump</name>
        <general-function>Transporter activity</general-function>
        <specific-function>Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.</specific-function>
        <gene-name>ABCB11</gene-name>
        <locus>2q24</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>63-83
148-168
216-236
241-261
320-340
354-374
756-776
795-815
870-890
891-911
980-1000
1012-1032</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.52</theoretical-pi>
        <molecular-weight>146405.83</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:42</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF091582</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3873243</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>778</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O95342</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCBB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family B member 11</synonym>
          <synonym>BSEP</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010492|Bile salt export pump
MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIW
LMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYDVELQELQIPGKACVNNTIVWTNSSLN
QNMTNGTRCGLLNIESEMIKFASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFR
RIMRMEIGWFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGFFRGWK
LTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVADEVISSMRTVAAFGGEKRE
VERYEKNLVFAQRWGIRKGIVMGFFTGFVWCLIFLCYALAFWYGSTLVLDEGEYTPGTLV
QIFLSVIVGALNLGNASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEI
EFHNVTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRFYDPCEGMVT
VDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYGREDATMEDIVQAAKEANAYNF
IMDLPQQFDTLVGEGGGQMSGGQKQRVAIARALIRNPKILLLDMATSALDNESEAMVQEV
LSKIQHGHTIISVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQSQG
NQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLSYLVHEPPLAVVDHKST
YEEDRKDKDIPVQEEVEPAPVRRILKFSAPEWPYMLVGSVGAAVNGTVTPLYAFLFSQIL
GTFSIPDKEEQRSQINGVCLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAML
GQDIAWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVAMIIAFSFSWKL
SLVILCFFPFLALSGATQTRMLTGFASRDKQALEMVGQITNEALSNIRTVAGIGKERRFI
EALETELEKPFKTAIQKANIYGFCFAFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRV
ISAVVLSATALGRAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDF
VDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMID
GHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDF
VMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVA
LDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPI
S</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010493|Bile salt export pump (ABCB11)
ATGTCTGACTCAGTAATTCTTCGAAGTATAAAGAAATTTGGAGAGGAGAATGATGGTTTT
GAGTCAGATAAATCATATAATAATGATAAGAAATCAAGGTTACAAGATGAGAAGAAAGGT
GATGGCGTTAGAGTTGGCTTCTTTCAATTGTTTCGGTTTTCTTCATCAACTGACATTTGG
CTGATGTTTGTGGGAAGTTTGTGTGCATTTCTCCATGGAATAGCCCAGCCAGGCGTGCTA
CTCATTTTTGGCACAATGACAGATGTTTTTATTGACTACGACGTTGAGTTACAAGAACTC
CAGATTCCAGGAAAAGCATGTGTGAATAACACCATTGTATGGACTAACAGTTCCCTCAAC
CAGAACATGACAAATGGAACACGTTGTGGGTTGCTGAACATCGAGAGCGAAATGATCAAA
TTTGCCAGTTACTATGCTGGAATTGCTGTCGCAGTACTTATCACAGGATATATTCAAATA
TGCTTTTGGGTCATTGCCGCAGCTCGTCAGATACAGAAAATGAGAAAATTTTACTTTAGG
AGAATAATGAGAATGGAAATAGGGTGGTTTGACTGCAATTCAGTGGGGGAGCTGAATACA
AGATTCTCTGATGATATTAATAAAATCAATGATGCCATAGCTGACCAAATGGCCCTTTTC
ATTCAGCGCATGACCTCGACCATCTGTGGTTTCCTGTTGGGATTTTTCAGGGGTTGGAAA
CTGACCTTGGTTATTATTTCTGTCAGCCCTCTCATTGGGATTGGAGCAGCCACCATTGGT
CTGAGTGTGTCCAAGTTTACGGACTATGAGCTGAAGGCCTATGCCAAAGCAGGGGTGGTG
GCTGATGAAGTCATTTCATCAATGAGAACAGTGGCTGCTTTTGGTGGTGAGAAAAGAGAG
GTTGAAAGGTATGAGAAAAATCTTGTGTTCGCCCAGCGTTGGGGAATTAGAAAAGGAATA
GTGATGGGATTCTTTACTGGATTCGTGTGGTGTCTCATCTTTTTGTGTTATGCACTGGCC
TTCTGGTACGGCTCCACACTTGTCCTGGATGAAGGAGAATATACACCAGGAACCCTTGTC
CAGATTTTCCTCAGTGTCATAGTAGGAGCTTTAAATCTTGGCAATGCCTCTCCTTGTTTG
GAAGCCTTTGCAACTGGACGTGCAGCAGCCACCAGCATTTTTGAGACAATAGACAGGAAA
CCCATCATTGACTGCATGTCAGAAGATGGTTACAAGTTGGATCGAATCAAGGGTGAAATT
GAATTCCATAATGTGACCTTCCATTATCCTTCCAGACCAGAGGTGAAGATTCTAAATGAC
CTCAACATGGTCATTAAACCAGGGGAAATGACAGCTCTGGTAGGACCCAGTGGAGCTGGA
AAAAGTACAGCACTGCAACTCATTCAGCGATTCTATGACCCCTGTGAAGGAATGGTGACC
GTGGATGGCCATGACATTCGCTCTCTTAACATTCAGTGGCTTAGAGATCAGATTGGGATA
GTGGAGCAAGAGCCAGTTCTGTTCTCTACCACCATTGCAGAAAATATTCGCTATGGCAGA
GAAGATGCAACAATGGAAGACATAGTCCAAGCTGCCAAGGAGGCCAATGCCTACAACTTC
ATCATGGACCTGCCACAGCAATTTGACACCCTTGTTGGAGAAGGAGGAGGCCAGATGAGT
GGTGGCCAGAAACAAAGGGTAGCTATCGCCAGAGCCCTCATCCGAAATCCCAAGATTCTG
CTTTTGGACATGGCCACCTCAGCTCTGGACAATGAGAGTGAAGCCATGGTGCAAGAAGTG
CTGAGTAAGATTCAGCATGGGCACACAATCATTTCAGTTGCTCATCGCTTGTCTACGGTC
AGAGCTGCAGATACCATCATTGGTTTTGAACATGGCACTGCAGTGGAAAGAGGGACCCAT
GAAGAATTACTGGAAAGGAAAGGTGTTTACTTCACTCTAGTGACTTTGCAAAGCCAGGGA
AATCAAGCTCTTAATGAAGAGGACATAAAGGATGCAACTGAAGATGACATGCTTGCGAGG
ACCTTTAGCAGAGGGAGCTACCAGGATAGTTTAAGGGCTTCCATCCGGCAACGCTCCAAG
TCTCAGCTTTCTTACCTGGTGCACGAACCTCCATTAGCTGTTGTAGATCATAAGTCTACC
TATGAAGAAGATAGAAAGGACAAGGACATTCCTGTGCAGGAAGAAGTTGAACCTGCCCCA
GTTAGGAGGATTCTGAAATTCAGTGCTCCAGAATGGCCCTACATGCTGGTAGGGTCTGTG
GGTGCAGCTGTGAACGGGACAGTCACACCCTTGTATGCCTTTTTATTCAGCCAGATTCTT
GGGACTTTTTCAATTCCTGATAAAGAGGAACAAAGGTCACAGATCAATGGTGTGTGCCTA
CTTTTTGTAGCAATGGGCTGTGTATCTCTTTTCACCCAATTTCTACAGGGATATGCCTTT
GCTAAATCTGGGGAGCTCCTAACAAAAAGGCTACGTAAATTTGGTTTCAGGGCAATGCTG
GGGCAAGATATTGCCTGGTTTGATGACCTCAGAAATAGCCCTGGAGCATTGACAACAAGA
CTTGCTACAGATGCTTCCCAAGTTCAAGGGGCTGCCGGCTCTCAGATCGGGATGATAGTC
AATTCCTTCACTAACGTCACTGTGGCCATGATCATTGCCTTCTCCTTTAGCTGGAAGCTG
AGCCTGGTCATCTTGTGCTTCTTCCCCTTCTTGGCTTTATCAGGAGCCACACAGACCAGG
ATGTTGACAGGATTTGCCTCTCGAGATAAGCAGGCCCTGGAGATGGTGGGACAGATTACA
AATGAAGCCCTCAGTAACATCCGCACTGTTGCTGGAATTGGAAAGGAGAGGCGGTTCATT
GAAGCACTTGAGACTGAGCTGGAGAAGCCCTTCAAGACAGCCATTCAGAAAGCCAATATT
TACGGATTCTGCTTTGCCTTTGCCCAGTGCATCATGTTTATTGCGAATTCTGCTTCCTAC
AGATATGGAGGTTACTTAATCTCCAATGAGGGGCTCCATTTCAGCTATGTGTTCAGGGTG
ATCTCTGCAGTTGTACTGAGTGCAACAGCTCTTGGAAGAGCCTTCTCTTACACCCCAAGT
TATGCAAAAGCTAAAATATCAGCTGCACGCTTTTTTCAACTGCTGGACCGACAACCCCCA
ATCAGTGTATACAATACTGCAGGTGAAAAATGGGACAACTTCCAGGGGAAGATTGATTTT
GTTGATTGTAAATTTACATATCCTTCTCGACCTGACTCGCAAGTTCTGAATGGTCTCTCA
GTGTCGATTAGTCCAGGGCAGACACTGGCGTTTGTTGGGAGCAGTGGATGTGGCAAAAGC
ACTAGCATTCAGCTGTTGGAACGTTTCTATGATCCTGATCAAGGGAAGGTGATGATAGAT
GGTCATGACAGCAAAAAAGTAAATGTCCAGTTCCTCCGCTCAAACATTGGAATTGTTTCC
CAGGAACCAGTGTTGTTTGCCTGTAGCATAATGGACAATATCAAGTATGGAGACAACACC
AAAGAAATTCCCATGGAAAGAGTCATAGCAGCTGCAAAACAGGCTCAGCTGCATGATTTT
GTCATGTCACTCCCAGAGAAATATGAAACTAACGTTGGGTCCCAGGGGTCTCAACTCTCT
AGAGGGGAGAAACAACGCATTGCTATTGCTCGGGCCATTGTACGAGATCCTAAAATCTTG
CTACTAGATGAAGCCACTTCTGCCTTAGACACAGAAAGTGAAAAGACGGTGCAGGTTGCT
CTAGACAAAGCCAGAGAGGGTCGGACCTGCATTGTCATTGCCCATCGCTTGTCCACCATC
CAGAACGCGGATATCATTGCTGTCATGGCACAGGGGGTGGTGATTGAAAAGGGGACCCAT
GAAGAACTGATGGCCCAAAAAGGAGCCTACTACAAACTAGTCACCACTGGATCCCCCATC
AGTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intercellular canaliculus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid-exporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>canalicular bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-exporting ATPase activity, phosphorylative mechanism</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>canalicular bile acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>